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Cardiovascular disease is common in Chronic Obstructive Pulmonary Disease 
(COPD), and forced expiratory volume in one second (FEV1) independently predicts 
cardiovascular morbidity and mortality. Pathological changes in the systemic 
vasculature have been proposed as potential mechanisms linking COPD to 
cardiovascular disease, and patients with COPD may be at increased risk of acute 
myocardial infarction during acute exacerbations. Notwithstanding causation, FEV1 
may be a useful prognostic marker in patients undergoing cardiac surgery. This thesis 
examined these three aspects of cardiovascular co-morbidity in relation to COPD and 
FEV1. 
In 2,241 consecutive cardiac surgery patients, FEV1 was associated with length of 
hospital stay (p<0.001) and mortality (p<0.001) adjusting for age, sex, height, body 
mass index, socioeconomic status, smoking, cardiovascular risk factors, chronic 
pulmonary disease, and type/urgency of surgery. 
In a survey of Scottish Respiratory Consultants there was no consensus regarding the 
investigation and management of acute coronary syndrome in exacerbation of 
COPD. In a case-series of 242 patients with exacerbations 2.5% (95% CI 1.0 to 
5.6%) had chest pain, raised serum troponin and serial electrocardiogram changes 
suggestive of acute coronary syndrome. However, over half reported chest pain, 
while raised troponin was not associated with chest pain or serial ECG changes. 
Carotid-radial pulse wave velocity (PWV), aortic distensibility, and aortic 
calcification were measured to assess the relationship of the systemic vasculature to 
FEV1 and  emphysema  severity  on  CT.  In  adjusted  analyses,  emphysema  was  
associated with PWV in patients with COPD (p = 0.006) and, in population based 
samples,  with  extent  of  distal  aortic  calcification  (p=0.02)  but  not  with  aortic  
distensibility (p=0.60). 
This thesis found that FEV1 was associated with mortality and length of hospital stay 
in patients undergoing cardiac surgery, and that chest pain and raised troponin were 
common but unrelated in exacerbation of COPD. In the vascular studies distal but 
not proximal vascular pathology was associated with FEV1, and if COPD is truly 
related to systemic arterial disease, the distal arterial tree is implicated. 
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1. Introduction 
1.1. COPD, definition and prevalence 
Over the past 10 years two major international guidelines and a national guideline 
have been produced for Chronic Obstructive Pulmonary Disease (COPD) by the 
American Thoracic Society/European Respiratory Society (ATS/ERS) (American 
Thoracic Society/European Respiratory Society 2004), the Global Initiative on 
Obstructive Lung Disease (GOLD) (Gold Executive Committee 2008), and the 
National Institute of Clinical Excellence (NICE) (NICE 2004). All three have 
provided definitions of the disease (Table 1-1). The presence of spirometry 
consistent with airflow limitation (forced expiratory volume in one second/forced 
vital  capacity  (FEV1/FVC)  ratio  <0.7)  which  does  not  fully  reverse  to  normal  lung  
function following bronchodilator administration is crucial to all three diagnoses, and 
each additionally states that airflow limitation is generally progressive in patients 
with COPD. The NICE guidelines definition does not require the administration of a 
bronchodilator before spirometry, but does have the additional criterion of FEV1 
percent  predicted  <80%.  The  central  role  of  smoking  as  the  cause  of  COPD  is  
emphasised in the NICE and ATS/ERS guidelines, and to a lesser extent in the 
GOLD guidelines. 
In an international cross-sectional study which employed random sampling methods 
to obtain population-based samples (n=9425, 12 sites), the prevalence of COPD 
defined  as  GOLD  stage  II  (FEV1/FVC  <0.7  and  FEV1 percent predicted <80%) in 
individuals  aged  40  or  over  was  11.8% for  men and  8.5% for  women (Buist  et  al.  
2007). Conservatively, this definition did not include all individuals with FEV1/FVC 
<0.7, which some authors have suggested leads to over diagnosis of COPD in older 
people (Hardie et al. 2002). 
Both GOLD and the ATS/ERS mentioned 'extra-pulmonary' or systemic 
‘manifestations’ in their definitions of COPD, reflecting the considerable recent 
interest in ‘co-morbidity’ in patients with COPD (Fabbri et al. 2008) from diseases 
such as osteoporosis, coronary heart disease, and from skeletal muscle dysfunction. 
Amongst these, cardiovascular disease has received particular attention. 
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Table 1-1 Definitions of COPD 





Chronic obstructive pulmonary disease (COPD) is a 
preventable and treatable disease state characterised by 
airflow limitation that is not fully reversible. The airflow 
limitation is usually progressive and is associated with an 
abnormal inflammatory response of the lungs to noxious 
particles or gases, primarily caused by cigarette smoking. 
Although COPD affects the lungs, it also produces 
significant systemic consequences. 
The diagnosis requires spirometry; post-bronchodilator 
FEV1/FVC <0.7 confirms the presence of airflow limitation 
that is not fully reversible. 
Gold Executive 
Committee 2008 
COPD is a preventable and treatable disease with some 
significant extra-pulmonary effects that may contribute to 
the severity in individual patients. Its pulmonary 
component is characterised by airflow limitation that is not 
fully reversible. The airflow limitation is usually 
progressive and associated with an abnormal inflammatory 
response in the lung to noxious particles or gases. 
Spirometry is essential … post-bronchodilator FEV1/FVC 
ratio <0.70. 
NICE 2004 Chronic obstructive pulmonary disease (COPD) is 
characterised by airflow limitation (FEV1 <80% predicted 
and FEV1/FVC <0.7). The airflow limitation is usually 
progressive, not fully reversible and does not change 
markedly over several months. The disease is 
predominantly caused by smoking. 
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1.2. FEV1, COPD and cardiovascular risk 
1.2.1. Cardiovascular mortality and morbidity are common in 
COPD 
A review of 130,000 death certificates from 1993 to 1999 in England and Wales 
found that, where obstructive lung disease was mentioned, ischaemic heart disease 
was recorded as the underlying cause of death in approximately 25% of cases 
(Hansell et al. 2003). In a similar design in a French population in the period from 
2000 to 2002, cardiovascular diseases were found in 32% of death certificates where 
COPD was  also  mentioned,  compared  to  22% where  it  was  not  (relative  risk  (RR)  
1.49; 95% CI 1.46 to 1.52) (Fuhrman et al. 2006). In the Tucson Epidemiologic 
Study of Airways Obstructive Disease 47% of men and 63% of women in whom 
obstructive  airways  disease  was  mentioned  as  a  contributing  cause  of  death  had  a  
circulatory  disease  as  the  primary  cause  of  death  (Camilli  et  al.  1991).  The  Lung  
Health Study recruited 5,887 smokers aged 35 to 46 with airflow limitation 
(FEV1/FVC  75% and FEV1 percent predicted from 50 to 90%) and reported deaths 
and hospitalisations at 5 years follow-up. 149 participants died and 754 were 
hospitalised  one  or  more  times  (Anthonisen  et  al.  2002).  All  deaths  and  all  
hospitalisations where the hospital records made a significant mention of respiratory 
or cardiovascular disease or cancer were independently reviewed by the study's 
mortality and morbidity review board. Twenty-five percent of deaths were due to a 
cardiovascular event, and cardiovascular disease accounted for 42% of first 
hospitalisations, whereas 14% of hospitalisations were due to respiratory causes. In a 
recent clinical trial of inhaled corticosteroids/long acting beta agonists in 8,184 
participants with moderate to severe COPD (FEV1 percent predicted <60%) 
members of a clinical endpoint committee independently adjudicated the cause of 
death in 911 cases, and found that 27% of all deaths were due to cardiovascular 
disease (McGarvey et al. 2007). Therefore, cardiovascular morbidity and mortality 
are common in patients with COPD. 
1.2.2. A diagnosis of COPD is associated with increased 
cardiovascular mortality and morbidity 
Evidence from secondary analyses of healthcare databases suggests that COPD may 
be a risk factor for increased cardiovascular morbidity and mortality. 
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In a study using the Saskatchewan healthcare database, COPD (n=11,493, defined on 
the basis of inhaled bronchodilator prescription in persons aged 40 or older) 
diagnosed from 1997-2000 was associated with a higher risk of hospitalisation with a 
cardiovascular event (risk ratio 1.17; 95% CI 2.00 to 2.33) after adjusting for 
cardiovascular events, diabetes, hypertension, and hypercholesterolemia compared to 
controls matched on age and sex (n=22,986) (Curkendall et al. 2006). In a similar 
study published a year earlier also using the Saskatchewan database, but in the period 
from 1990 to 2007, a diagnosis of COPD (defined on the basis of treatment with 
inhalers or methylxanthines) was also associated with an increased risk of 
hospitalisation (RR 1.89; 95% CI 1.83 to 1.94, adjusting for age, sex and calendar 
year) and mortality (standardised mortality ratio 1.95; 95% CI 1.83 to 2.07) from 
cardiovascular disease compared to the general Saskatchewan population (Huiart et 
al. 2005). 
Similarly, a retrospective matched cohort study Sidney et al. (2005) examined 
associations between diagnosis with COPD (defined on the basis of COPD code on 
discharge, and two prescriptions for inhaled bronchodilator therapy) using a database 
from a prepaid integrated health-care system in California. Controls were matched on 
gender, year of birth, length of membership in scheme, and the analyses adjusted for 
age, gender, hypertension, hyperlipidemia, diabetes, and previous coronary heart 
disease. COPD predicted increased risk of hospitalisation (RR 1.87; 95% CI 1.69 to 
2.08) and death (RR 1.85; 95% CI 1.55 to 2.21) from myocardial infarction. 
However, these studies obtained morbidity and mortality data from routine sources 
such as death certificates, which can lead to diagnostic misclassification. Moreover, 
data on smoking and other potential confounders was either absent or incomplete 
which may have resulted in confounding. More crucially, patients given a diagnosis 
of  COPD  are  likely  to  differ  from  those  not  diagnosed  with  COPD  in  terms  of  
socioeconomic status, access to and use of healthcare and presence of co-morbid 
disease, which means the observed associations could have arisen from selection 
bias. 
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1.2.3. Reduced FEV1 is a predictor of increased 
cardiovascular mortality 
Nevertheless, FEV1, which is reduced in COPD, has been found to predict 
cardiovascular mortality in a number of longitudinal analyses from cohorts widely 
dispersed in time and place. A recent systematic review of longitudinal studies 
summarised results from studies with 500 or more subjects in which FEV1 and 
cardiovascular mortality was reported (Sin et al. 2005). Twelve studies met pre-
specified quality criteria (of 30 meeting the inclusion and exclusion criteria, from 
340 initially identified) comprising a total of 83,880 individuals. The reports were 
published over three decades from 1970 to 2000, and presented data obtained in the 
UK,  the  US  and  continental  Europe.  All  twelve  found  that  low  FEV1 predicted 
cardiovascular mortality, and in a meta-analysis the pooled estimate for the relative 
risk of cardiovascular disease for those in the group with the lowest lung function 
compared to those in the group with the highest lung function was 1.99 (95% CI 1.71 
to 2.29). The various studies used a variety of analytical strategies, and statistical 
adjustment was made for a range of potential confounding factors including age, 
gender, race/ethnicity, socioeconomic status, smoking status, smoking pack years, 
blood pressure, diabetes, cholesterol, and patient medications. Similar associations 
have  also  been  described  for  the  peak  expiratory  flow  rate  another  marker  of  lung  
function (Persson et al. 1986). 
Estimates of the proportion of smokers who develop abnormal lung function vary 
(Lundback et al. 2003), but smoking causes both impaired lung function (Scanlon et 
al. 2000) and coronary heart disease (Kawachi et al. 1994). Smoking is therefore 
likely to at least partly confound any association between FEV1 and cardiovascular 
disease. Unsurprisingly, each study of lung function and coronary heart disease 
adjusted for smoking. However, exposure to cigarette smoke is difficult to measure. 
Indeed, the best established measure of exposure, pack years (pack years = number 
of years smoked x no. of cigarettes smoked per day / 20) is based upon individual 
patient recall, and takes no account of the amount of smoke inhaled per cigarette. As 
such, a plausible explanation for any association between FEV1 and cardiovascular 
risk is residual confounding from cigarette smoke exposure. Nevertheless, FEV1 also 
appears to predict cardiovascular mortality amongst never smokers, defined as 
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individuals who have smoked less than 100 cigarettes in their lifetime (Hole et al. 
1996; Strachan 1992) suggesting that the association between FEV1 and 
cardiovascular disease may be genuinely independent of the effects of cigarette 
smoke exposure. 
Therefore, since COPD is the commonest cause of reduced FEV1 in adults, evidence 
from population-based studies support the view that cardiovascular risk is increased 
in COPD, independently of established cardiovascular risk factors. 
However, in population-based studies adjusting for potential confounders, FEV1 is 
associated with ischaemic heart disease mortality in a broadly linear fashion. In the 
Midspan study the relative risk in quintiles one though four compared to the fifth 
quintile were 1.56, 1.48, 1.55 and 1.15 respectively for men, and 1.88, 1.50, 1.22 and 
1.01 respectively for women (Hole et al. 1996). Similarly, in the NHANES cohort, in 
quintiles one though four compared to the fifth quintile the relative risk of mortality 
from ischaemic heart disease was 5.65, 3.11, 3.69 and 1.50 respectively (Sin et al. 
2005). Therefore, there was no threshold above which higher FEV1 did not predict a 
lower risk of adverse outcomes, which suggests that FEV1 may be a broad marker of 
cardiovascular risk, rather than that COPD is a specific cause of cardiovascular 
disease.  
Nevertheless, on a population scale the magnitude of the association between FEV1 
and cardiovascular risk is considerable. Indeed, in the Midspan study the population 
attributable of risk (PAR) of death from coronary heart disease associated with being 
in the lowest quintile of FEV1 percent predicted compared to the highest quintile of 
FEV1 percent predicted was 26.2; 95% CI 18.6 to 33.8 for men, and 23.9; 95% CI 
13.8 to 34.0 for women. This PAR was similar to that obtained for elevated serum 
cholesterol for men (PAR 20.5; 95%CI 12.8 to 28.2) and women (PAR 24.8; 95% CI 
14.9 to 34.7) (Hole et al. 1996). 
1.3. Mechanisms linking FEV1/COPD and cardiovascular 
risk 
The potential relevance of the complex relationships between impaired pulmonary 
function, COPD, cigarette smoke exposure and other environmental pollutants and 
co-morbid disease was discussed in an editorial as early as 1978 (Cohen 1978). 
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Despite  this  the  mechanisms  underlying  the  association  between  FEV1 and 
cardiovascular disease have not been extensively studied. FEV1 and COPD might 
cause or be associated with any of several steps on the pathway towards clinical 
cardiovascular disease; i.e. the formation and development of atheromatous plaques, 
plaque rupture, thrombus formation, myocardial cell death, clinical morbidity 
(angina, heart failure, arrhythmia etc) and death, or with diagnostic activity. 
One reason for this relative inattention is that FEV1 is not specific to cardiovascular 
disease, and predicts a broad range of adverse health outcomes including cancer from 
all causes, non-respiratory cancer, rupture of aortic aneurysm, and psychiatric illness 
(Pembroke et al. 2006; Hole et al. 1996; Brown & Powell 1999). Therefore, FEV1 
may be a broad marker of poor health, making it less likely that it is a cause of 
cardiovascular morbidity and mortality. 
However, more recently several authors have proposed that potentially modifiable 
biological mechanisms may explain the association between COPD and 
cardiovascular disease, including endothelial dysfunction, systemic inflammation, 
alteration in platelet function and clotting factors, and a systemic susceptibility in the 
connective tissues causing both emphysema and vascular disease (Sin & Man 2003; 
MacNee et al. 2008). 
1.4. Atheroma and arterial stiffness 
1.4.1.  FEV1 and COPD and associations with atheroma 
Several studies have examined associations between atheroma and FEV1, using a 
variety of methods, including ultrasound which can measure intimal medial thickness 
and plaque thickness (usually defined as localised areas of thickness >1mm or 
>1.5mm), doppler ultrasound which measures stenosis, ankle-arm pressure index 
(pressure transducers at toe and thumb) and ankle-brachial index 
(sphygmomanometer measures pressure at brachial artery and ankles), lower 
pressures in the lower limbs implies stenosis in arteries supplying the lower limbs, 
calcium scoring (wherein calcium detected on CT scan is quantified and regions of 
calcification are proxies for calcified atherosclerotic plaques, and coronary 
angiography (wherein the coronary artery is cannulated radio-opaque dye is injected 
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and x-ray screening is used to identify coronary artery anatomy and regions of 
stenosis and occlusion). 
In a cross-sectional study Ebrahim et al. (1999) measured plaque burden via B-mode 
ultrasound  at  the  common  carotid  artery  (IMTcca)  and  at  the  bifurcation  of  the  
carotid artery (IMTbif). The 425 men sampled were selected from the British 
Regional Heart Study cohort, and the 375 women were selected from a random 
sample of the age-sex register of general practices (the sampling frame from which 
the  British  Regional  Heart  Study  was  originally  drawn).  Response  rates  were  83%  
for men and 69% for women. In an analysis adjusting for age, height-standardised 
FEV1 (categorised in tertiles) was statistically significantly inversely associated with 
IMTcca in men and women (p<0.05), and IMTbif was higher in men in the lowest 
tertile for height-standardised FEV1, although this was not statistically significant 
(confidence intervals not provided). There was no association with the presence of 
carotid plaques, but the confidence intervals were broad (in men odds ratio 0.72; 
95% CI 0.4 to 1.2). The intra and inter observer reproducibility of the ultrasound 
measurement of IMT and plaque thickness was good, but the measurement was not 
blinded. Furthermore, spirometry is technically difficult to perform, and quality 
control measures were not reported. Moreover, neither adjustment nor stratification 
was used to control for confounding by cigarette smoke exposure. 
In 220 male smokers from a 1914 Swedish Birth Cohort Engström et al. (2001) 
tested for an association between FEV1 aged 55 and 65, and the presence of sub-
clinical leg or carotid atheroma aged 68 (composite endpoint). FEV1 was measured 
via spirometry when the men were aged 55 and again aged 68 and was standardised 
by height on both occasions. Atheroma was measured indirectly at both sites at age 
68. Carotid stenosis was assessed using doppler ultrasound, and leg atheroma was 
measured using the systolic ankle–arm pressure index. After adjusting for current 
tobacco consumption aged 55 and 68, hypertension (high blood pressure), diabetes 
and alcohol consumption aged 68, the authors found associations between height-
standardised FEV1 aged 55 and aged 68 and presence of atheroma aged 68 (0.5 litre 
increase in FEV1; OR 0.76 (95%CI 0.57 to 0.998), and OR 0.79 (95%CI 0.62 to 
0.998) respectively). Similar associations were found for FVC. The authors 
concluded that the association was unlikely to be due to confounding by smoking. 
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However, residual confounding by smoking appears probable since only smoking 
status, and not lifetime cigarette smoke exposure was measured. Moreover, only 220 
of the 389 smokers originally enrolled had their plaque burden assessed aged 68 (due 
to deaths, emigration, refusals etc) so selection bias may also account for the 
association. Furthermore, there was no record of whether those assessing plaque 
burden were blinded to the lung function results. 
In the largest study to examine this question Schroeder et al. (2005) examined lung 
function and markers of plaque burden in 14,480 participants obtained by probability 
sampling in the Atherosclerosis Risk in Communities (ARIC) Study. Carotid 
atheroma was measured as carotid intimal medial thickness via B-mode ultrasound, 
and carotid plaque was identified as wall thickness >1.5mm and other criteria. 
Atheroma in the leg was identified via the ankle brachial index (ABI). All 
measurements, including spirometry were performed to a high standard. Crucially, 
Schroeder et al. stratified by smoking status and reported associations amongst never 
smokers. FEV1 was associated with atheroma burden in the leg measured via ABI, 
even amongst never smokers and after adjusting for age, gender, race, study centre, 
height, height-squared, and established cardiovascular risk factors (FEV1 was 2.97 
litres, 95%CI 2.95 to 2.98, in the ‘lowest’ plaque burden group and was 2.83 litres, 
95%CI 2.83 to 2.95, in the ‘highest’ plaque burden group). 
The only longitudinal study found was published by (Zureik, Kauffmann, et al. 
2001). 1389 participants aged 59 to 71 were recruited in Western France from the 
electoral register without random sampling and through advertising (Bonithon-Kopp 
et al. 1996). From among this group, 656 individuals had Peak Expiratory Flow Rate 
(PEFR) measurement and carotid B-mode ultrasound performed at baseline, and after 
2 and 4 years. PEFR is an alternative measure of lung function which can be 
performed more quickly using more portable equipment than spirometry, and is itself 
a predictor of cardiovascular mortality (Persson et al. 1986). In this study, PEFR was 
standardised by age and height using sex-specific reference equations (relative 
PEFR). Of 656 subjects, 110 had incident carotid plaque disease, defined as the 
presence of a new lesion which was 1mm or thicker, encroaching onto the vessel 
lumen. Incident cases were defined as individuals with new plaques, even if plaques 
were already present at other sites on the artery wall. 
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In logistic regression models low relative peak flow at baseline was associated with 
incident plaque burden (lowest quintile of peak flow compared to highest quintile, 
(OR 3.07; 95% CI 1.62 to 5.85, follow-up period was 4 years). This association 
persisted after adjustment for age, sex, body mass index, hypertension, 
hypercholesterolemia, diabetes, smoking habits, alcohol consumption, common 
carotid artery intima-media thickness, and the presence of carotid plaques at baseline 
(OR 2.84; 95% CI 1.45 to 5.71). 
The longitudinal design may partly account for the effect of potential unmeasured 
confounders. In addition, the authors performed a range of sensitivity and sub-group 
analyses, including amongst never smokers, to which the findings proved robust. 
Surprisingly however, there was no association between baseline plaque disease and 
baseline relative peak flow, and only a small difference in CIMT between the highest 
and lowest quintiles. Furthermore, it is not biologically plausible that low PEFR 
could cause (or be a consistent marker of the risk of) new atheromatous plaque 
formation aged 60 over a 4 year period. As such, the reported association may well 
have been a chance finding, or the consequence of observer bias, particularly as the 
ultrasound assessments of plaque burden were not blinded, and there is considerable 
subjectivity in the measurement of plaque burden the authors employed. 
In January 2009 a case-control study was published, in which healthy Japanese men 
presenting  at  an  occupational  health  service  had  been  recruited  (Iwamoto  et  al.  
2009). From 2,037 attendees the authors identified 1,054 subjects without diabetes, 
impaired glucose tolerance or respiratory diseases (other than COPD). From among 
the 1,054, the authors selected sixty-one cases with airflow limitation on spirometry 
and  a  history  of  smoking  of  ten  or  more  pack  years.  Each  participant  was  
individually matched to four controls without airflow limitation, two smokers and 
two non-smokers. B-mode ultrasound was used to measure carotid IMT, and the 
authors defined atheromatous plaque disease as a localised area of thickness greater 
than 1.5mm. The authors found that carotid intimal medial thickness was increased 
in the group with airflow limitation (0.78mm in cases, and 0.73 mm in each of the 
control groups, p<0.01, confidence intervals not presented). They also found that 
plaques were commoner amongst smokers with airflow limitation. There were a 
number of strengths in this study, including the fact that cases and controls were 
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obtained from the same sampling frame, and that the ultrasonographer was blinded to 
the subjects status as case or control. 
However, the statistical analysis did not take into account the fact that the cases and 
controls were individually matched. Use of an unconditional analysis is likely to 
produce wider standard errors than a conditional one, but may also overestimate the 
effect size. Similarly, the authors attempted to adjust for differences in a variety of 
potential confounders (eg high cholesterol) using linear and logistic regression, but  
did so using stepwise methods, which may have missed important confounders. 
Unlike the carotid arteries, the coronary arteries cannot be readily assessed using 
ultrasound techniques, and invasive or radiation-based methods are needed to assess 
the plaque burden. Four studies were found which examined these measures, two of 
which were published only in abstract form. 
Barr et al. (2007) examined the association between FEV1 and the coronary arteries, 
in The Multi Ethnic Study of Atherosclerosis (MESA). MESA used random 
telephone number dialling to recruit individuals from six US communities. 
Individuals with clinically evident coronary heart disease were excluded from the 
study. Coronary artery plaque burden was measured using coronary artery calcium 
scoring, and carotid artery plaque burden was measured using carotid IMT via 
ultrasound. Lung function was measured using spirometry to determine FEV1 and 
FVC. A wide range of potential confounders were measured. In 3,226 individuals, 
IMT at the internal carotid artery was inversely associated with FEV1 (1.28 mm thick 
in the group with worst lung function, compared to 1.03 mm thick in the group with 
the best lung function, p<0.001, no confidence interval presented). However, after 
adjusting for age, sex, race, education, smoking, pack years, body mass index, 
diabetes, fasting plasma glucose, hypertension, systolic and diastolic blood pressure, 
low density lipoprotein, high density lipoprotein, and C-reactive protein (CRP), only 
a weak association was found (p=0.05). Furthermore, there was no evidence of an 
association between coronary artery calcium score and low FEV1 (p=0.86, no 
confidence interval presented).  It  is  difficult  to assess the quality of this work from 
an abstract presentation. However, the sample used was drawn using probability 
sampling from a relevant population, the measures of plaque burden were performed 
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blind and to a high technical standard, and the authors adjusted for a wide range of 
possible confounders. Nevertheless, the restriction to individuals without clinical 
cardiovascular disease may have caused the investigators to miss an important 
association. 
In a retrospective chart review in 1720 consecutive patients who self-presented at a 
cardiac imaging centre coronary artery calcium measures and lung images were 
obtained using electron beam computed tomography scans. Seventy-eight (5%) of 
patients had emphysema identified qualitatively on CT scan, and raised coronary 
artery calcium was commoner in this group than in the remaining 1642 patients 
without emphysema on CT scan (31% vs 19%, p=0.01). However, although age, sex, 
hypertension and smoking status were independently associated with having a raised 
coronary artery calcification score, emphysema on CT scan was not (Alhaj et al. 
2008). 
In work submitted for an MSc dissertation, published solely in abstract form 
(McAllister et al. 2009), I examined whether FEV1 was associated with the Gensini 
score, a quantitative score of plaque burden derived from coronary angiography 
(Gensini 1983). 2,241 patients were identified in the Lothian Cardiac Surgery 
Database aged>40 years who had surgery from 2001 to 2007. Using name, date of 
birth, and postcode these cases were linked to local spirometry and angiography 
databases. Spirometry and angiography records were available for 93.2% and 93% of 
cases respectively. Following angiography the degree of stenosis in 14 epicardial 
arterial segments, estimated visually, is recorded. After excluding patients with 
restrictive spirometry (n=234) FEV1 was not associated with Gensini Score after 
adjusting for age, sex, height and weight (n=1709, 0.02 ml; 95% CI -0.62 to 0.66 ml, 
p=0.95). Similar results were found after also adjusting for social class, smoking 
status, diabetes and hypertension, with alternative measures of coronary burden, and 
if FEV1/FVC or FEV1 percent predicted was used in place of FEV1. These findings 
were consistent with those reported by Barr et al from the MESA study. 
However,  this   was   a   secondary   analysis   of   data   obtained   from   a   clinical   
sample.  Sampling was not random, and selection bias is therefore an important 
consideration, particularly as both lung function and coronary angiography are likely 
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to be related to reasons for selection for surgery. There was no adjustment for pack 
years smoking, and therefore confounding was possible, but unlikely to account for 
the null association between FEV1 and angiographic burden. 
The most recent study examining the association between lung function and 
atheroma examined coronary artery calcification and FEV1 using routine data in 
4,905 men aged  40 (Park et al. 2009). In 2005-2008 6,446 men attending a health 
promotion centre for an annual health check were recruited, with 1,537 excluded 
because of a history of previous CHD, more than one attendance, or because 
metabolic/lung function measures were not performed/not available (n=79, 151, and 
1,307 respectively). Coronary artery calcium scores were calculated using ECG 
gated scans from a single multidetector (MDCT) scanner (Philips, Brilliance 40). In 
analyses adjusting for age, smoking status and BMI participants in the lowest quartile 
of FVC percent predicted and FEV1 percent predicted had higher odds of having any 
coronary calcification (Agaston score >0) than those in the highest quartile (OR 1.22; 
95% CI 1.02 to 1.46, and OR 1.31; 95% CI 1.09 to 1.58 respectively). 
Since almost a quarter of patients were excluded because of missing lung 
function/metabolic measures, selection bias might explain these findings, particularly 
since no details were provided as to how the excluded patients differed from those 
included in the main sample. More significantly, the study did not report findings for 
never smokers, or adjust for pack years smoke exposure, and therefore confounding 
by cigarette smoke exposure may explain the findings. 
In summary, several studies have examined associations between FEV1 or COPD 
and markers of atheroma, with variable results. Plaque burden measured at different 
sites and in different populations appears to have different associations with lung 
function. The strongest evidence was for atheroma in the arteries supplying the lower 
limbs, as a reduced ankle-brachial index was associated with FEV1 even in never 
smokers  after  adjustment  for  a  range  of  established  cardiovascular  risk  factors.  No 
published study appears to have imaged the aorta or iliac arteries and related 
calcification at these sites to FEV1. Chapter 7 addresses this issue by examining 
associations between FEV1, FVC and emphysema measures and calcification in the 
aorta from the proximal ascending aorta to the iliac arteries. 
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1.4.2.  FEV1 and COPD and associations with measures of 
arterial stiffness 
Arterial stiffness can be measured at the local, regional and systemic level using a 
number  of  techniques  (Laurent  et  al.,  on  behalf  of  the  European  Network  for  Non-
invasive Investigation of Large Arteries 2006). Local measures of arterial stiffness 
examine a particular site (e.g. the proximal 4 cm of the brachial artery) and can be 
obtained via both ultrasound and MR scanning, wherein the systolic and diastolic 
area are measured, and the difference is divided by the distending pressure to 
calculate the distensibility. Systemic measures of arterial stiffness can be derived 
from the pulse wave-form using a model of arterial function by obtaining a tracing of 
the radial pulse using a high sensitivity tonometer (e.g. the augmentation index 
(Atcor Medical 2008). Finally, regional arterial stiffness can be measured as the 
pulse wave velocity (PWV) across a vascular region (Figure 1-1). 
 
Figure 1-1 Selected arterial stiffness measures 
The fact that pressure waves travel faster through stiffer materials than less stiff 
materials, and therefore that the speed of the arterial pressure wave is proportional to 
the arterial stiffness across each region, can be derived from Newton’s second law of 
motion (Nichols & O’Rourke 1990) . PWV can be measured across several arterial 
regions, although only carotid-femoral PWV has been validated in longitudinal 
studies as a predictor of cardiovascular risk (Laurent et al., on behalf of the European 
Network for Non-invasive Investigation of Large Arteries 2006). Carotid-femoral 
PWV measures PWV across the thoracic and abdominal aorta and iliac artery, 
whereas carotid-radial PWV measures PWV across the aorta and brachial artery. 
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PWV can be measured using MR and ultrasound as well as by applanation tonometry 
but only the latter has been used in studies relating PWV to FEV1 or COPD. 
Measurement of applanation tonometry for carotid-radial PWV is illustrated in 
Figure 1-2. Briefly the length, along the body surface, between the sternal angle and 
the radial artery is measured, and the length from the sternal angle to the carotid 
artery, and the difference between the two is used to estimate the distance the wave 
travels between the heart and the site of the radial artery pulse. Similarly the 
difference in time is measured from the R-wave recorded on a simultaneous ECG to 
detection of the pressure wave at the carotid and radial pulses. The PWV is then 
calculated from these two measures. Carotid-femoral PWV is similar, except that the 
body surface measurement is made from the sternal angle to the femoral rather than 
the radial artery pulse, and the tonometer is placed at the femoral artery rather than 
the radial artery. 
 
Figure 1-2 Carotid-radial PWV by applanation tonometry 
Aortic distensibility can be measured via transthoracic ultrasound and by cardiac 
magnetic resonance (MR) and is a well-validated measure of local aortic stiffness 
(Oliver & Webb 2003). Aortic cross-sectional area is measured in systole and 
diastole, the distending pressure is measured or estimated, and the aortic 
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distensibility is calculated as 1000 x (maximum area – minimum area) / (minimum 
area x brachial pulse pressure). 
Several measures of arterial stiffness (carotid-femoral PWV, aortic distensibility, and 
to a lesser extent carotid-radial PWV) have been associated with measures of 
coronary atheroma burden (coronary artery calcium scoring, coronary flow reserve 
and intravascular ultrasound)(Giannattasio et al. 2007; Gullu et al. 2006; Kullo et al. 
2006; McLeod et al. 2004; van Popele et al. 2006), while both cardiac MR aortic 
distensibility and carotid-femoral PWV are associated with markers of endothelial 
dysfunction (Gullu et al. 2006; Newby et al., with McEniery et al., Yasmin 2006) and 
peripheral microvascular dysfunction (Cheung et al. 2007; Mitchell et al. 2005). 
Aortic stiffness is also believed to cause adverse physiological effects through 
increased central pulse pressure and increase left ventricular afterload (Laurent et al., 
on behalf of the European Network for Non-invasive Investigation of Large Arteries 
2006). 
Several  studies  have  examined  measures  of  arterial  stiffness  in  relation  to  FEV1 or 
COPD. Sabit et al reported that carotid-femoral PWV was higher in 74 patients with 
COPD than in 42 controls matched on age and sex (11.4 and 8.5 m/s respectively), 
and augmentation index (a systemic measure of arterial stiffness) was also higher 
(Sabit et al. 2007). However, the cases and controls differed in terms of current 
smoking (48% vs 14%) and lifelong smoke exposure (median 50 vs 15 pack years). 
Previous hypertension was also commoner in the COPD group (34% vs 21%). The 
recruitment of cases and controls was not described, and it may be that the observed 
differences are due to selection bias, particularly if cases were recruited from a 
population attending secondary care. The authors employed multiple linear 
regression,  but  the  regression  was  performed  across  cases  and  controls  without  
specifically modelling case/control status, and a stepwise approach was used rather 
than including potential confounders such as smoking status in the final model. As 
such, the differences Sabit et al observed in carotid-femoral PWV between cases and 
controls may be due to confounding from smoking status or lifelong cigarette smoke 
exposure, or previous hypertension, as well as from unmeasured confounders, as a 
result of selection bias. 
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Some of these deficiencies were addressed by Maclay et al in a case-control study in 
men, 19 with COPD and 17 controls, in which differences in carotid-femoral PWV 
of a similar magnitude were observed (11.2 and 9.2 respectively) (Maclay, 
McAllister, Mills, Paterson, et al. 2009). Inclusion was restricted to ex-smokers who 
had stopped for at least 3 months, without known cardiovascular disease (including 
hypertension) with a 10 or more pack year smoking history. Matching on pack years 
between cases and controls was close (median [IQR] 35 [35–48] and 34 [28–46] 
respectively). 
However, both studies used case-control designs, and in neither study were cases and 
controls recruited from a sampling frame of a known population. Consequently, 
sampling bias might explain the differences between COPD patients and controls. 
Moreover, neither study employed blinding. 
Nevertheless, two population based studies have reported an association between 
carotid-femoral PWV and reduced FEV1, of which COPD is the commonest cause in 
older adults. 
Zureik et al found that carotid-femoral PWV was associated with FEV1 and FVC in 
men  after  adjusting  for  age,  height,  weight,  diabetes,  smoking  status,  hypertension  
and hypercholesterolaemia (2.5 m/s increment in PWV was associated with a 193ml 
decrement  in  FEV1 and 158ml decrement in FVC (r2=0.07, p <0.001 and r2=0.05 p 
<0.006 respectively) (Zureik, Benetos, et al. 2001). The participants were recruited 
from one centre of a general health screening program offered to residents in Paris, 
France. The association between PWV and lung function was assessed using FEV1 
and FVC as continuous variables whereas potential confounders such as cholesterol 
and BP were dichotomised, which may have resulted in residual confounding. 
However, this is unlikely to account for the observed associations as adjusting for 
these dichotomous variables had minimal effect on the strength of association 
between FEV1 and FVC and carotid-femoral PWV. 
A key finding of Zureik et al was that FEV1 and FVC had similar associations with 
PWV in a subgroup analysis of never smokers adjusting for the same covariates as in 
the main analysis (r2=0.07 and r2=0.04 respectively), although the definition of never 
smoker used by the authors was not provided. 
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Bolton et al also examined carotid-femoral PWV in a population-based sample of 
men (n=827) in Caerphilly in Wales, UK, finding that FEV1 was associated with 
carotid-femoral PWV after adjusting for age group, height, mean arterial pressure, 
heart rate and smoking (beta-coefficient not given, p <0.001) (Bolton et al. 2009). 
The authors found that adjusting for smoking status did not affect the strength of the 
association between FEV1 and carotid-femoral PWV. The association was weaker in 
never-smokers but a global test for interaction with smoking status was not 
statistically significant (p-interaction >0.30, coefficients not provided). 
In sub-group analyses Bolton et al additionally adjusted for early life factors (n=288, 
self-reported birth weight, childhood and adult socioeconomic status), systemic 
inflammation (n=211, CRP, blood viscosity and white cell count) and metabolic 
factors (n=313, body mass index, homeostasis model assessment (insulin resistance), 
serum triglycerides, and systolic blood pressure) in order to identify a mechanism 
linking FEV1 and  PWV.  None  of  these  variables  attenuated  the  strength  of  the  
association between FEV1 and PWV. However, as acknowledged by the authors, this 
may be due to deficiencies in the measures chosen, for example self-reported birth 
weight as a proxy for actual birth weight, rather than because none of these variables 
lie on the causal pathway. 
However, in a study of 678 Japanese-Americans (male and female), Taneda et al 
found no association between carotid-femoral PWV and either FEV1 or FVC, 
adjusting for age, sex, body mass index, total cholesterol/high density lipoprotein 
cholesterol ratio, hypertension, diabetes and smoking status (never, ex-smoker, or 
current) (Taneda et al. 2004). The authors dichotomised all exposures, outcomes and 
covariates, and the odds ratio for the association between high PWV and reduced 
FEV1 percent predicted (<80%) was broad 1.39 (95% CI 0.82-2.34). However, 
although dichotomisation can reduce the power of an analysis, this cannot account 
for the lack of association as the findings were also null when PWV, FEV1 and FVC 
were analysed as uncategorised raw values. 
As such, the difference in findings between the European studies and that of Taneda 
et al may be due to differences in population, such as the low prevalence of current 
smoking (12%) or other differences in environmental exposures. 
  35 
Alternatively, the different associations may reflect the different commercial tools 
used to measure PWV. Taneda et al used the PWV-200 velocimeter (Fukuda Denshi, 
Tokyo, Japan) while the European studies used the SphygmoCor device (AtCor 
Medical Pty Ltd., Sydney, Australia). The former device standardises the result to a 
diastolic blood pressure of 80mmHg while the latter does not. Nor is there any 
standardisation across devices, and they are likely to differ in their susceptibility to 
particular errors or biases (Xu 2003). 
Systemic inflammation, endothelial dysfunction and systemic and pulmonary 
connective tissue susceptibility have all been proposed as mechanisms linking FEV1 
and COPD to measures of systemic vascular pathology such as arterial stiffness and 
atheroma.  
1.4.3. Systemic inflammation and oxidative stress 
Systemic inflammation is now a well established feature of reduced FEV1 and of 
COPD. In a systematic review FEV1 was associated with increased CRP, circulating 
platelets, leukocyte and fibrinogen (Sin & Man 2003), interleukin-6 (Il-6) (Walter et 
al. 2008) while Tumour Necrosing Factor alpha (TNF- ), CRP and oxidised lipids 
are increased in COPD (Gan et al. 2004; Santus et al. 2005). Spill-over from lung 
inflammation, hypoxia-induced production of inflammatory mediators and skeletal 
muscle dysfunction have been proposed as potential mechanisms for systemic 
inflammation and oxidative stress in COPD (Maclay et al. 2007). 
The role of systemic inflammation as a causal factor in coronary heart disease 
remains controversial. In a meta-analysis of 22 population-based prospective studies 
CRP, which has been most extensively studied, was associated an increased risk of 
incident CHD (7068 cases, OR 1.6), and in animal models CRP has been implicated 
in plaque development, but genetic studies exploiting ‘Mendelian randomisation’ to 
examine  the  effect  on  CHD  risk  of  single  nucleotide  polymorphisms  known  to  
increase CRP have so far had no association with coronary heart disease (Casas et al. 
2008). However, these studies have been underpowered to detect moderate effects, 
and the effects of haplotypes for other inflammatory markers have not been 
investigated. Fibrinogen may be of particular interest, as it predicts longitudinal 
decline in lung function (Jiang et al. 2008). 
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Systemic inflammation is associated with arterial stiffness cross-sectionally, 
(Mahmud & Feely 2005) and predicts incident arterial stiffness longitudinally 
(Mattace-Raso et al. 2010), while TNF-  and oxidised lipids have been implicated in 
vascular  calcification  (Tintut  et  al.  2000;  Parhami  et  al.  1997).  Therefore  systemic  
inflammation and oxidative stress is one possible mechanism linking FEV1 and 
COPD with vascular pathology. 
1.4.4. Endothelial dysfunction 
Endothelial regulation of vascular smooth muscle cells acutely alters arterial 
stiffness, and endothelial dysfunction is associated with PWV and aortic 
distensibility (Gullu et al. 2006; Newby et al., with McEniery et al., Yasmin 2006). 
Endothelial dysfunction is also found with acute cigarette smoke exposure (Newby et 
al. 1999). Endothelial vasomotor function has been found to be impaired in patients 
with COPD compared to controls when measured via flow-mediated dilation 
(Eickhoff et al. 2008), but not via forearm plethysmography (Maclay, McAllister, 
Mills, Paterson, et al. 2009). In older former smokers flow-mediated dilation has also 
been found to be associated with FEV1 and emphysema severity on CT scan (Barr,  
Mesia-Vela, et al. 2007). 
Two competing hypotheses are found in the published literature concerning systemic 
endothelial dysfunction in COPD. Maclay and Eickhoff hypothesised that COPD 
causes increased systemic inflammatory markers which impair endothelial function, 
while Barr et al measured FMD in the systemic circulation as a marker of pulmonary 
endothelial function in order to test the hypothesis that cigarette smoke exposure 
causes emphysema and COPD through its effects on pulmonary endothelial cells. In 
the latter view systemic and pulmonary endothelial dysfunction are associated 
because both are affected by cigarette smoke exposure. Either mechanism could 
explain the observed associations between systemic vascular pathology and FEV1 
and COPD. 
1.4.5. Connective tissue susceptibility 
There are a number of pathological features common to arterial stiffness and 
emphysema which suggest that, in some individuals with COPD, there may be an 
acquired or inherited tendency to develop emphysema and arterial stiffness. Elastin 
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loss (Shifren & Mecham 2006), and increased alveolar septal thickening (Lang et al. 
1994) occur in emphysema, while in stiff arteries elastin fragmentation is found, 
along with increased numbers of collagen fibres, and increased vessel lumen size and 
thickness (Zieman et al. 2005). In humans, a polymorphism in gelatinase B (MMP-9) 
is associated with increased risk of arterial stiffness (Medley et al. 2004; Zhou et al. 
2007) as well as upper zone emphysema (Ito et al. 2005). In Marfan’s syndrome 
increased aortic root stiffness is well described and has important clinical 
consequences, and people with Marfan's may also develop emphysema even in the 
absence of cigarette smoke exposure (Pyeritz 2000). 
Increased levels of MMP-9 are found both in bronchoalveolar lavage (Finlay et al. 
1997) and sputum (Boschetto et al. 2006) in subjects with emphysema, and levels of 
MMP-9 are increased in the serum of subjects with arterial stiffness (Wallace et al., 
with Yasmin 2005). MMP-12 (macrophage elastase) knockout mice are protected 
against cigarette smoke induced emphysema compared to wild-type mice 
(Hautamaki et al. 1997), and MMP-12/apoE deficient mice are protected against 
elastin degradation in atherosclerosis compared to single deficiency apoE mice 
(Luttun et al. 2004). Finally, the Klotho mouse (a model of accelerated ageing) 
develops early-emphysema, loss of skin elasticity and increased arterial stiffness 
(Kuro-o et al. 1997).  Subjects with emphysematous phenotype of COPD may 
therefore  have  a  systemic  susceptibility  to  lung,  skin,  and  arterial  connective  tissue  
damage. 
Lung and artery susceptibility to connective tissue damage could be due to 
congenital variation in the synthesis, destruction and/or repair of extra cellular 
matrix. Unmeasured factors such as low birth weight, poor diet, recurrent infection, 
and environmental pollution might plausibly increase the susceptibility of both the 
lung and vasculature to connective tissue destruction, particularly in early life 
(Cheung et al. 2004; Martyn & Greenwald 1997; Kajekar 2007; Mills et al. 2005). 
Furthermore, recent evidence that COPD may have an autoimmune component 
characterised by an abnormal immune response to elastin (Lee et al. 2007) is of 
interest, as an autoimmune mechanism might explain associations between COPD, 
loss of skin elasticity and arterial stiffness. 
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1.5. Exacerbation of COPD and cardiovascular risk 
1.5.1. Definition, incidence, pathophysiology and aetiology 
of exacerbations 
There is no universally accepted clinical or pathological definition, but exacerbation 
of COPD has been defined pragmatically in statements by the National Institute for 
Clinical Excellence and the European Respiratory and American Thoracic Societies 
(NICE 2004; American Thoracic Society/European Respiratory Society 2004). These 
definitions are based upon a consensus definition reached at the 1999 Aspen Lung 
Conference in which European and American physicians arrived at a pragmatic 
definition of exacerbation of COPD as “a sustained worsening of the patient’s 
condition, from the stable state and beyond normal day-to-day variation, that is acute 
in onset and necessitates a change in regular medication in a patient with underlying 
COPD” (Rodriguez-Roisin 2000). The ATS/ERS definition mirrors that of the Aspen 
conference, while the NICE guideline qualifies the statement on the necessity for 
treatment, instead stating that exacerbations ‘often’ require a change in treatment. 
Alternative definitions of exacerbation have been used in studies employing diary 
cards to identify exacerbations on a background of daily symptoms (Seemungal et al. 
1998), and in studies focussed specifically on exacerbations of infectious aetiology 
(Anthonisen et al. 1987). 
During acute exacerbations of COPD there is increased local and systemic 
inflammation and oxidative stress, increased airflow limitation as a result of mucosal 
oedema, mucus plugging and bronchospasm, dynamic hyperinflation, and 
hypoxaemia and acidosis (Fujimoto et al. 2005; Hurst et al. 2006; Praticò et al. 1998; 
O’Donnell & Parker 2006). The relative contribution of different pathogens and 
exposures to the aetiology of exacerbations remains controversial (Anzueto et al. 
2007), although traditionally bacterial pathogens were believed to account for around 
50% of exacerbations with the remainder being caused by viruses and air pollution 
(Sapey & Stockley 2006). 
The reported incidence of exacerbations depends upon the definition employed and 
whether they are counted via diary cards, self-report, or from healthcare utilisation 
data. Nevertheless, exacerbations are a common cause of morbidity and mortality 
regardless of the methods used. According to data published by the Information 
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Services  Division  (ISD)  of  the  National  Health  Service  
(http://www.isdscotland.org/isd/4334.html, Accessed June 2008) discharge from 
hospital in Lothian with a diagnosis of exacerbation of COPD was common with 
almost 5 exacerbations per 100 person years amongst men and women aged 65 to 74 
(Table 1-2). 
Exacerbations of COPD contribute to increased mortality and worse quality of life in 
patients with COPD (Soler-Cataluna et al. 2005; Seemungal et al. 1998) 
Table 1-2 Discharges from hospital in Lothian with a diagnosis of 
exacerbation of COPD 
 Year n Rate per 100,000 
population 
All Ages 2002/03 2648 340 
 2003/04 3098 397 
 2004/05 3024 384 
 2005/06 2992 377 
 2006/07 3396 424 
    
Ages 65 to 74 2002/03 800 3383 
 2003/04 959 4064 
 2004/05 1026 4331 
 2005/06 1023 4295 
 2006/07 1129 4697 
1.5.2. Exacerbations and cardiovascular risk 
Although cardiovascular co-morbidity is common in COPD, the role of 
exacerbations has not been extensively studied, and published guidelines do not 
address whether and how patients with exacerbations of COPD should be 
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investigated or treated for acute cardiac disease (Gold Executive Committee 2008; 
American Thoracic Society/European Respiratory Society 2004; NICE 2004). 
COPD and FEV1 are both associated with increased cardiovascular risk (Sections 
1.2.2 and 1.2.3). Evidence from two studies which performed secondary analyses of 
data obtained from healthcare databases suggest that the risk of myocardial infarction 
may be further increased during exacerbations in patients with COPD (Huiart et al. 
2006; Donaldson et al. 2010). 
Huiart  et  al  identified  a  cohort  of  5,658  patients  with  COPD  on  the  basis  of  a  
minimum of 3 prescriptions within a 12-month period of inhaled oral beta-agonists, 
methylxanthines, or ipratropium from 1990 to 1997 from the Saskatchewan 
healthcare database. A nested case-control design was used to compare 371 cases 
with acute myocardial infarction to 1,864 controls. Using acute oral corticosteroid 
prescription as a proxy for acute exacerbation of COPD, Huiart et al found that 
exposure to oral corticosteroid therapy within the past 14 days was associated with 
an increased odds ratio for acute myocardial infarction (OR 2.01; 95% CI 1.13 to 
3.58) adjusting or matching for age, duration of disease, sex, number of prescriptions 
of bronchodilators, inhaled corticosteroid use, hospitalisation within the past 3 
months, diabetes, hypertension, known ischaemic heart disease and heart failure. The 
highest odds ratio was found with prescriptions of steroids equivalent to 25mg of 
prednisolone or more daily (OR 3.22). Oral steroid prescription within the previous 
15 to 60 day period was not associated with an increased risk of myocardial 
infarction. 
This study used routine data and did not report the results of any validation or quality 
control making coding errors likely. If non-differential then any such errors in the 
outcomes or exposures would tend to bias the effect estimates towards the null, but 
non-differential errors in the covariates can cause residual confounding. More 
importantly, the authors did not adjust for current smoking status, pack years or 
FEV1 and therefore unmeasured confounding may explain the finding that 
exacerbations were associated with increased risk of myocardial infarction. 
Moreover, given the short duration between exposure and outcome, symptoms from 
unstable angina leading up to acute myocardial infarction may have been 
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misdiagnosed as exacerbation of COPD. The resulting misclassification would tend 
to produce a spurious correlation between exacerbations and myocardial infarction. 
Donaldson et al identified 25,857 patients with COPD from a UK primary care 
database using Quality and Outcomes Framework codes (a healthcare management 
tool). Myocardial infarction was defined a priori on the basis of Read codes (coding 
system used in primary care throughout the UK) and there were 1.1 cases per 100 
patient years. Three definitions were used for exacerbations on the basis of acute 
prescriptions (1) oral coroticosteroids >20mg/day, (2) selected antibiotics 
(penicillins, cephalosporins, tetracyclines, macrolides, sulphonamides and 
quinolones) and (3) both (1) and (2). 
In a self-controlled case series design, conditional Poisson regression was used to 
estimate incidence rate ratios (IRRs). There was no association in the  "high-risk" 
period of 7 weeks (49 days) post exacerbation, which had been chosen a priori, for 
any of the definitions of exacerbation (all definitions p>0.45). However, using 
exacerbation definition 3 (both steroid and antibiotic prescription) the 1 to 5 day 
period post-exacerbation period was associated with increased risk of myocardial 
infarction (IRR 2.27; 95% CI 1.1 to 4.7, p=0.03), with the other two definitions 
having weaker associations in the same direction which were not statistically 
significant (antibiotics IRR 1.14; 95% CI 0.7 to 1.8, p=0.57, steroids IRR 1.55; 95% 
CI 0.9 to 2.8; p=0.15). 
Since Donaldson et al used a study design where each patient acted as their own 
control, the issue of confounding was adequately addressed. However, as routine 
data were used misclassification between exacerbations and myocardial infarction 
remains an issue, particularly as the diagnoses of exacerbation were made in primary 
care, where fewer clinical investigations are available. A further possibility is that 
this was a Type 1 error, particularly since risk of myocardial infarction in the 1 to 5 
day post exacerbation period was not chosen a priori as the exposure for the main 
analysis. 
Nevertheless, both reports are consistent with previous findings that acute lower 
respiratory tract infection and acute exposure to air pollution transiently increase the 
risk of myocardial infarction (Meier et al. 1998; Forastiere et al. 2005). 
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Moreover, the association between exacerbation of COPD and myocardial infarction 
is  biologically  plausible.  The  pathological  features  of  exacerbation  of  COPD  
described in Section 1.5.1 such as increased systemic inflammation, tachycardia and 
hypoxia might be expected to favour plaque rupture and thrombus formation. 
Moreover, raised CRP, Il-6, fibrinogen and increased platelet activation have been 
reported  in  exacerbations  of  COPD,  compared  to  the  stable  state,  (Wedzicha  et  al.  
2000; Hurst et al. 2006; Maclay, McAllister, Mills, Newby, et al. 2009) and 
inflammation is implicated in plaque rupture and thrombus formation (Libby 2002). 
It  is  not known whether there is  clinical  consensus regarding the diagnosis of acute 
coronary syndrome in patients with exacerbation with COPD, nor is the prevalence 
of acute coronary syndrome in patients with exacerbation of COPD known. 
1.6.  FEV1 as a prognostic marker 
Notwithstanding causation, FEV1 is of interest as a prognostic marker. FEV1 has 
been  found  to  predict  a  range  of  adverse  events  in  addition  to  cardiovascular  risk,  
including cancer from all causes, non-respiratory cancer, rupture of aortic aneurysm, 
and psychiatric illness (Pembroke et al. 2006; Hole et al. 1996; Brown & Powell 
1999). 
Several prognostic indices have been developed to help patients and clinicians decide 
whether cardiac surgery is appropriate. The European System for Cardiac Operative 
Risk  Evaluation  (EuroSCORE) is  a  widely  used  risk  prediction  tool  that  comprises  
seventeen clinical features (Nashef et al. 1999), and has good discrimination for early 
and late post-operative mortality (Nilsson et al. 2006). 
However, because of an ageing population and changes in surgical practice over the 
last decade these clinical tools need to be updated (Nashef 2009), and since FEV1 is a 
robust measure of respiratory physiology, and a strong predictor of adverse outcomes 
in a range of settings, it should be evaluated for inclusion in new risk prediction 
tools. 
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1.7. Summary and aims 
Therefore, cardiovascular morbidity and mortality are common in COPD, having 
been diagnosed with COPD is associated with increased cardiovascular risk, and 
FEV1 independently predicts cardiovascular morbidity and mortality. 
Systemic vascular pathology has been proposed as a mechanism linking FEV1 and 
COPD to cardiovascular morbidity and mortality, through various processes 
including systemic inflammation, endothelial dysfunction and susceptibility to 
connective tissue degradation. 
Previous studies have identified that patients with COPD may be at increased risk of 
acute myocardial infarction during acute exacerbations, perhaps through 
pathophysiological changes such as hypoxia, tachycardia, and increased systemic 
inflammation. 
Notwithstanding causation, the strong associations between FEV1 and  a  variety  of  
adverse outcomes mean that it may be a useful prognostic marker in patients 
undergoing cardiac surgery. 
1.7.1. Hypotheses 
Therefore, this thesis will address the following hypotheses:- 
1 FEV1 is a potentially useful prognostic marker in patients undergoing 
cardiac surgery. 
2 Exacerbation of COPD partly accounts for the association between 
cardiovascular morbidity and mortality and COPD/airflow limitation, and 
acute coronary syndrome is common in exacerbation of COPD. 
3 Pathological changes in the systemic vasculature partly mediate the 
association between COPD/ reduced FEV1 and cardiovascular morbidity and 
mortality. 
1.7.2. Aims 
To address these broad hypotheses, this thesis has the following aims:- 
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• To test the hypothesis that FEV1 predicts  length  of  hospital  stay  and  in-
hospital mortality in patients undergoing cardiac surgery. Chapter 2. 
• To  identify  whether  there  is  a  clinical  consensus  amongst  Scottish  
Respiratory Consultants regarding the investigation of patients for acute 
coronary syndrome following admission to hospital with exacerbation of 
COPD. Chapter 3. 
• To identify the prevalence of acute coronary syndrome in patients admitted 
to hospital with exacerbations of COPD in a prospective case-series. Chapter 
4. 
• To test  the hypothesis that  the extent of arterial  stiffness is  associated with 
the severity of emphysema in patients with COPD. Chapter 5. 
• To test the hypothesis that arterial stiffness in the proximal aorta, measured 
via reduced distensibility of the ascending aorta on magnetic resonance 
(MR),  is  associated  with  severity  of  emphysema  and  reduced  FEV1 in a 
large population-based cohort, including participants with airflow limitation. 
Chapter 6. 
• To test the hypothesis that decrements in the FEV1 and increments in percent 
emphysema on computed tomography (CT) scans are associated with 
calcification of the vasculature from the ascending aorta to the iliac arteries. 
Chapter 7. 
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2. Analysis of routine data: FEV1 predicts higher 
mortality and prolonged length of stay in patients 
undergoing cardiac surgery 
2.1. Introduction 
For more than 40 years cardiac surgery has been performed to relieve symptoms and 
improve outcomes in patients with coronary artery and valvular heart disease (Eagle 
et al. 2004). Whilst improvements in surgical technique have resulted in progressive 
reductions in operative morbidity and mortality, the aging population and increasing 
use of percutaneous treatments have resulted in older patients with more co-
morbidity being referred for cardiac surgery (Peterson 2009). 
Several prognostic indices have been developed to help patients and clinicians decide 
whether cardiac surgery is appropriate. The European System for Cardiac Operative 
Risk  Evaluation  (EuroSCORE) is  a  widely  used  risk  prediction  tool  that  comprises  
seventeen clinical features (Nashef et al. 1999), and has good discrimination for early 
and late post-operative mortality (Nilsson et al. 2006). It is recognised that changes 
in surgical practice over the last decade require these clinical tools to be updated 
(Nashef 2009). With increasingly elderly patients being considered for surgical 
management, markers which reflect general physiological reserve and severity of co-
morbid disease may be particularly relevant to prognosis and should be evaluated for 
inclusion in new risk prediction tools. 
FEV1 is a robust accurate measure of pulmonary physiology, and is a strong 
predictor of mortality from cardiovascular, respiratory and other causes, independent 
of age, gender, race/ethnicity, socioeconomic status, blood pressure, diabetes and 
cholesterol (Hole et al. 1996; Friedman et al. 1976). However, studies directly 
examining whether FEV1 predicts outcomes in cardiac surgery have been limited to 
small numbers of patients with chronic pulmonary disease (Fuster et al. 2006; Lizak 
et al. 2009). As such, the relationship between FEV1 and clinical outcomes following 
cardiac surgery has not been established.  
Therefore, the aim of this chapter is to test the hypothesis that FEV1 predicts hospital 
stay and in-hospital mortality, and that this association is independent of having a 
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clinical history of pulmonary disease and other potential confounders including age, 
sex, smoking and socioeconomic status. 
2.2. Methods 
2.2.1. Study population 
In a retrospective cohort study all patients aged 40 years or older who underwent 
coronary artery bypass grafting (CABG) and/or valve repair or replacement surgery 
from January 1st 2001 to December 31st 2007 at the Royal Infirmary of Edinburgh, 
Scotland, United Kingdom were identified. Patients who were not resident in the 
hospital catchment area or who underwent cardiac surgery as an emergency were 
excluded a priori on the basis that spirometry would not have been performed locally 
or would not have been feasible prior to surgery. Where patients had more than one 
operation during the study period, only the first operation was included. 
2.2.2. Clinical characteristics and outcomes 
Patient characteristics and details of their cardiac surgery, including length of 
hospital stay and in-hospital mortality, were obtained from medical records and 
recorded in an electronic cardiac surgical database (TOMCAT Clinical Systems, 
Philips Healthcare, Amsterdam, The Netherlands) by trained staff at the time of 
admission. This database is maintained to nationally agreed standards, which 
includes auditing of randomly sampled medical records and publication of statistics 
on missing data (Society for Cardiothoracic Surgery in Great Britain and Ireland 
2008). In an external Scottish Quality Improvement Programme audit in 2008 these 
data were found to be 98.5% accurate. 
An estimate of predicted operative mortality was derived using the EuroSCORE 
(Nashef  et  al.  1999).  The  EuroSCORE  defines  ‘chronic  pulmonary  disease’  as  the  
long term use of bronchodilators or steroids for lung disease. In addition to ‘chronic 
pulmonary disease’, patient or clinician reported diagnoses of chronic obstructive 
pulmonary disease (COPD) and asthma were also recorded. The 2006 Scottish Index 
of Multiple Deprivation (SIMD) score was obtained from the recorded postal code 
and patients were stratified based on the national distribution of the SIMD in order to 
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provide an area-based measure of socio-economic status (Scottish Government 
2005). 
2.2.3. Spirometry 
Height and weight were measured, and spirometry was performed, without the 
administration of a bronchodilator, on a wedge bellows spirometer to Association for 
Respiratory Technology and Physiology/British Thoracic Society standards (Model 
S, Vitalograph, Buckinghamshire, UK) by trained clinical physiologists in one of two 
lung function laboratories in Edinburgh. FEV1 percent predicted was calculated using 
the European Coal and Steel reference equations (Quanjer et al. 1993). Airflow 
limitation  was  defined  a  priori  as  an  FEV1/FVC ratio below 0.7 and FEV1 percent 
predicted less than 80% (NICE 2004). A broader definition of airflow limitation for 
use in sensitivity analyses included all patients with an FEV1/FVC ratio below 0.7 
regardless of the FEV1 percent predicted. 
2.2.4. Record linkage 
Records from the cardiac surgery database were linked to the spirometry database for 
the same period. Within a secure health service environment date of birth, first name 
and surname were used to link records using Microsoft Access 2000. Personal 
identifiers and dates were removed following linkage and the irreversibly 
anonymised database was used for analysis. Where patients had spirometry 
performed  more  than  once  prior  to  surgery,  the  measure  closest  to  the  date  of  the  
operation  was  selected.  Patient  selection  and  matching  were  completed  prior  to  all  
analyses. 
2.2.5. Statistical analysis 
For descriptive purposes, characteristics were compared for patients with and without 
spirometry records and by quintile of FEV1 percent predicted, which is widely used 
in clinical practice. However, use of the current European prediction equations has 
been criticised on the grounds that they are not contemporary and were not obtained 
from original data (Degens & Merget 2008). As such all formal analyses were 
performed using FEV1 with  adjustment  for  age,  sex,  height  and  other  covariates  as  
appropriate. Proportional change in length of stay, and the odds ratio for in-hospital 
mortality were estimated by quintile of FEV1, and per one standard deviation 
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decrement in FEV1, using linear regression (log-transformed) and logistic regression 
respectively. 
Discrimination  of  the  existing  EuroSCORE  model  was  compared  to  a  model  
including EuroSCORE and FEV1 using  the  area  under  the  curve  (DeLong  et  al.  
1988), and the more sensitive net reclassification and integrated discrimination 
indices (NRI and IDI respectively) (Pencina et al. 2008). The NRI compares models 
with and without a new marker of interest to estimate the proportion of patients more 
appropriately classified minus the proportion less appropriately classified under the 
new model. The IDI is a global measure of sensitivity weighted by specificity that is 
more sensitive than the area under the curve. Model calibration was compared using 
the  le  Cessie-van  Houwelingen  normal  test  statistic  for  the  unweighted  sum  of  
squared errors (Hosmer et al. 1997). 
In sensitivity analyses regression modelling was repeated following stratification by 
gender, smoking status, type and urgency of operation, and following exclusion of 
patients with a clinical history of asthma, COPD and ‘chronic pulmonary disease’ or 
airflow limitation on spirometry. Generalised additive models were used to explore 
non-linearity.  Where  data  were  missing,  multiple  imputation  was  used  as  the  main  
approach with listwise deletion sensitivity analyses. Analyses were performed in 
SAS 9.2 (Cary, North Carolina, USA) and R version 2.9.2 (R Foundation for 
Statistical Computing, Vienna, Austria).  
2.3. Results 
Records meeting matching criteria were available for 2,082 patients (93%) of the 
2,241 patients from the regional cardiac surgery database who met the eligibility 
criteria. The 159 patients without spirometry were more likely to have required 
urgent surgery (70 versus 54%, p<0.001), undergone previous surgery, and have a 
clinical history of COPD (3.8 versus 1.3%, p=0.02), but were otherwise similar to the 
2,082 with matching records (Table 2-1). There were observed differences, of 
doubtful significance, in body mass index and prevalence of renal disease. 
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Table 2-1 Characteristics of patients with and without spirometry 
measures 
 Spirometry No spirometry p-value 
n 2082 159  
Age, years 67 (10) 68 (9) 0.07 
Gender, male 1451 (69.7%) 115 (72.3%) 0.49 
Deprivation (SIMD) 
  First quintile 
  Second quintile 
  Third quintile 
  Fourth quintile 















Type of Operation 
  CABG 
  CABG and Valve 






















Previous cardiac surgery * 112 (5.4%) 16 (10.1%) 0.02 
Height, cm 167 (9) 167 (9) 0.35 
Weight, kg 78.7 (15.6) 77.1 (16.6) 0.20 
Body Mass Index, kg/m2 28.0 (4.7) 27.0 (4.8) 0.02 
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 Spirometry No spirometry p-value 
n 2082 159  
Smoking Status 
  Never Smoked 
  Ex-Smoker 











Diabetes 351 (16.9%) 34 (21.4%) 0.15 
Hypertension 1311 (63.6%) 93 (59.2%) 0.27 
Renal Disease* 34 (1.6%) 9 (5.7%) <0.003 
Extracardiac Disease 199 (9.6%) 19 (11.9%) 0.33 
Extracardiac Disease 199 (9.6%) 19 (12%)  
Previous Stroke or TIA 217 (10.4%) 18 (11.3%) 0.75 
Recent Myocardial 
Infarction 
1248 (60%) 103 (64.8%) 0.23 
Atrial Fibrillation 181 (15.3%) 17 (20.7%) 0.15 
Angina 
  CCS0 
  CCS1 
  CCS2 
  CCS3 
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 Spirometry No spirometry p-value 
n 2082 159  
Dyspnoea 
  NYHA 1 
  NYHA 2 
  NYHA 3 































































10 (0.96%) 3 (1.89%) 0.26 
COPD* 28 (1.3%) 6 (3.8%) 0.02 
Asthma* 24 (1.3%) 2 (1.26%) 0.91 
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Mean (standard deviation) except where count (%). T-test for continuous measures 
and Chi-squared test for counts, except * where Fisher’s exact test was used. 
In patients with spirometry performed the mean (SD) age was 67 (10) years and 
1,451 (70%) were male (Table 2). Spirometry was performed in the same year as 
surgery in 90% of patients, and in the same or previous year in 97%. Most patients 
had a history of cigarette smoking with 52% ex-smokers and 15% current smokers, 
but a clinical diagnosis of COPD was only recorded in 28 (1.3%), asthma in 24 
(1.2%) and ‘chronic pulmonary disease’ in 20 (1.0%) patients. Airflow limitation 
identified on spirometry (FEV1/FVC <0.7 and FEV1 <80% predicted) was present in 
318 (15%) patients. 
Socioeconomic deprivation, urgent surgery, valve procedures, current smoking, 
diabetes mellitus, stroke, extra-cardiac arteriopathy (defined in the euroSCORE code 
as a history of claudication, documented carotid artery occlusion or >50% stenosis, 
or surgery for disease of the abdominal aorta, peripheral vasculature or carotid 
arteries), left ventricular impairment, pulmonary hypertension, atrial fibrillation and 
dyspnoea were more frequent in quintiles with lower FEV1 percent predicted than 
those in higher quintiles, but the proportion of patients with a >70% stenosis in one 
or more of the main coronary arteries was similar across FEV1 percent predicted 
quintiles (Table 2-2). 
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Table 2-2 Patient characteristics by quintile of FEV1 percent predicted 
 Q1 Q2 Q3 Q4 Q5 













n 416 417 416 417 416 
Age, years (mean (SD)) 69 (9) 66 (10) 66 (10) 66 (10) 68 (10) 
Gender, male 68.3 70.0 71.4 72.4 66.4 
Deprivation (SIMD) 
  First quintile (most) 
  Second quintile 
  Third quintile 
  Fourth quintile 































Height, cm – mean (SD) 168 (9) 168 (9) 168 (9) 168 (9) 166 (10) 








28.0 (4.6) 27.6 (4.3) 
Smoking status 
  Never smoked 
  Ex-smoker 





















Previous cardiac surgery 8.4 7.9 5.5 2.6 2.4 
Diabetes 19 18 17 16 13 
Hypertension 59 66 64 63 67 
Renal disease 5 1 1 1 1 
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 Q1 Q2 Q3 Q4 Q5 













n 416 417 416 417 416 
Previous stroke or TIA 15 9 11 11 6 
Extracardiac arteriopathy 11 12 10 8 6 
Recent myocardial 
infarction 
63 60 58 60 57 
Atrial fibrillation 27 17 13 14 6 
Vessels >70% stenosis 
  None 
  One 
  Two 





















Left ventricular ejection 
fraction 
  Normal 
  Moderately impaired 





















Pulmonary hypertension  30 27 20 6 11 
Type of operation      
  CABG 53.6 63.1 67.6 67.9 67.3 
  CABG and valve 14.2 13.0 12.3 10.3 13.2 
  Valve 32.2 24.0 20.2 21.8 19.5 
Urgent surgery 59.6 52.0 55.3 52.3 50.5 
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Values are percentages unless stated 
2.3.1. Length of stay 
Median hospital stay was 3 days longer amongst patients in the lowest quintile for 
FEV1 compared to patients in the highest quintile (1.53-fold longer; 95% CI 1.41-
1.67; p<0.001), and this association persisted after adjusting for age, sex, height, 
weight, type of operation, urgency of procedure, deprivation score, smoking status, 
recent myocardial infarction, extracardiac arteriopathy, diabetes, hypertension, 
stroke, atrial fibrillation, left ventricular function, asthma, COPD, bronchodilator use, 
preoperative renal failure, and pre-operative angina and dyspnoea (1.35-fold longer; 
95% CI 1.20-1.52; p<0.001) (Table 2-3). 
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Table 2-3 Length of stay by quintile of FEV1 
 Q1 Q2 Q3 Q4 Q5 SD decrement in FEV1 
p-value 









(3.16-5.80) (800 ml) 
 
n 416 417 416 417 416   
LOS in days, median (IQR) 10 (7-15) 8 (7-13) 7 (6-10) 7 (6-9) 7 (6-8)   
Relative LOS unadjusted 1.53 1.40 1.25 1.10 1 
1.17 <0.001 
(95% CI) (1.41-1.67) (1.29-1.52) (1.15-1.36) (1.01-1.20)  1.14-1.20  
Relative LOS - model 1 
1.53 1.38 1.21 1.07 1 1.17 <0.001 
(95% CI) (1.36-1.71) (1.25-1.53) (1.11-1.33) (0.98-1.16)  1.12-1.21  
Relative LOS - model 2 
1.35 1.30 1.16 1.05 1 1.12 <0.001 
(95% CI) (1.20-1.52) (1.17-1.44) (1.05-1.27) (0.96-1.14)  1.07-1.17  
Relative LOS – proportional change in length of stay relative to reference category 
Model 1 - adjusted for age, sex, height and body mass index 
Model 2 – as model 2 additionally adjusting for type of operation, urgency of procedure, deprivation score, smoking status, recent 
myocardial infarction, extracardiac arteriopathy, diabetes, hypertension, stroke, atrial fibrillation, left ventricular function, asthma, COPD, 
chronic pulmonary disease, preoperative renal failure, pre-operative angina, pre-operative dyspnoea. 
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2.3.2. Mortality 
Strong associations were found for in-hospital mortality and FEV1 (Table 2-4). The 
unadjusted odds ratio (OR) for in-hospital death was 2.58-fold higher (95% CI 1.95-
3.41; p<0.001) per standard deviation decrement in FEV1 (800 ml). FEV1 remained a 
strong predictor after adjusting for type of operation, smoking status, asthma, COPD, 
bronchodilator use, pre-operative angina and pre-operative dyspnoea (OR 2.11; 
95%CI 1.45-3.08; p<0.001, Table 2-4). 
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Table 2-4 In-hospital mortality by quintile of FEV1 
 Q1 Q2 Q3 Q4 Q5 SD decrement in FEV1 
p-value 









(3.16-5.80) (800 ml) 
 
n 416 417 416 417 416   
Mortality, n (%) 36 (8.7%) 16 (3.8%) 12 (2.9%) 3 (0.7%) 4 (1.0%)   
Odds Ratio unadjusted 9.76 4.11 3.06 0.75 1 2.58 <0.001 
(95% CI) (3.44-27.7) (1.36 12.41) (0.98-9.57) (0.17-3.36)  1.95-3.41  
Odds Ratio - model 1 8.61 3.73 2.94 0.74 1 2.53 <0.001 
(95% CI) (2.58-28.81) (1.13-12.33) (0.91-9.53) (0.16-3.36)  1.78-3.60  
Odds Ratio - model 2 5.23 2.76 2.28 0.69 1 2.11 <0.001 
(95% CI) (1.48-18.41) (0.81-9.36) (0.69-7.53) (0.15-3.15)  1.45-3.08  
Model 1 - adjusted for age, sex, height and body mass index 
Model 2 - as model 1 additionally adjusting for type of operation, smoking status, COPD, chronic pulmonary disease, pre-operative angina, 
pre-operative dyspnoea.  
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2.3.3. Airflow limitation on spirometry and FEV1 
Adjusting for the same covariates as in the main analyses, FEV1 continued to predict 
hospital stay (800ml decrement in FEV1; 1.26-fold longer; 95% CI 1.08-1.48, 
p<0.001), and mortality (800ml decrement in FEV1; 2.28 OR; 95% CI; 1.19-4.41; 
p=0.01) after excluding individuals with airflow limitation on spirometry. Similar 
results  were  obtained  when  a  broader  definition  of  airflow  limitation  was  used  
(FEV1/FVC ratio <0.70, regardless of FEV1 percent predicted, p<0.001, and p=0.01 
respectively). The associations between FEV1, length of stay and mortality appeared 
to be broadly linear (Figure 2-1), with no formal evidence for departure from 
linearity for either outcome (p=0.13, and p=0.28 respectively). Nor is there evidence 
of departure from linearity graphically, at least until the FEV1 is  over 4 litres,  after 
which the data are relatively sparse.
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Figure 2-1 Association between FEV1 and length of stay and mortality 
a) Relative length of stay for a given FEV1 compared to the length of stay for the mean FEV1. b) Odds ratio for in-hospital mortality for a 
given FEV1 compared to the odds ratio for the mean FEV1. Estimates were obtained from generalized additive models using a loess 
smoothing function . A rug plot illustrates the density of the data for given value of FEV1. Significance tests for non-linearity were p=0.11 
and p=0.28 respectively.  
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2.3.4. FEV1 compared to the EuroSCORE 
 FEV1 remained strongly associated with mortality after adjusting for the 
EuroSCORE (OR 1.69; 95% CI 1.23-2.31, likelihood ratio statistic 11, 1 df, p 
<0.001). The area under the receiver operator characteristic curve (AUC) was higher 
for EuroSCORE than FEV1, but the difference was not statistically significant (AUC 
0.78 and 0.74 respectively, p=0.15, Figure 2-2). Similarly, the addition of FEV1 to 
the EuroSCORE increased the AUC when compared to the EuroSCORE alone (AUC 
of 0.80 and 0.78 respectively), but the difference was not statistically significant 
(p=0.26).  
 
Figure 2-2 Areas under the receiver operator curve for EuroSCORE and 
for FEV1 
However, using a more sensitive measure of discrimination, the Net Reclassification 
Index (Pencina et al. 2008), 27% of patients (95% CI 4 to 51%, p <0.001) were more 
appropriately classified with the EuroSCORE alone than with FEV1 alone, while 
36% of patients (95% CI 12-59%; p=0.003) were more appropriately classified when 
FEV1 was combined with the EuroSCORE compared to the EuroSCORE alone. The 
Integrated  Discrimination  Index  yielded  similar  results  for  each  of  these  
comparisons: EuroSCORE alone versus FEV1 alone (IDI 0.02; 95% CI 0.00 to 0.03; 
p=0.01) and EuroSCORE alone versus FEV1 in combination with EuroSCORE 
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(IDI=0.01; 95% CI 0.00 to 0.02; p=0.006). Model calibration was also better with 
FEV1 and EuroSCORE combined (z=0.14; p=0.89) than with the EuroSCORE alone 
(z =1.27, p=0.21). 
2.3.5. Sensitivity analyses 
Similar associations were found for length of stay and mortality after stratifying by 
operation type and urgency, gender and smoking status. Results obtained using 
listwise deletion were similar to those obtained using multiple imputation. 
2.4. Discussion 
FEV1 is a strong predictor of longer hospital stay and in-hospital mortality following 
elective and urgent cardiac surgery. These associations persist after adjusting for 
multiple covariates including a clinical diagnosis of COPD, and airflow limitation on 
spirometry. Addition of FEV1 to the current and most widely used peri-operative risk 
prediction model, the EuroSCORE, improved discrimination and calibration for in-
hospital mortality. 
COPD is the commonest cause of reduced FEV1 in adults (Bednarek et al. 2008), and 
is an established risk factor for in-hospital and long-term mortality following cardiac 
surgery (Clough et al., for the Northern New England Cardiovascular Disease Study 
Group 2002; Rosenthal et al. 2003; Leavitt et al., for the Northern New England 
Cardiovascular Disease Study Group 2006). Two recent studies confirm that FEV1 is 
associated with poorer outcome in patients with chronic lung disease undergoing 
cardiac surgery, however due to the small number of patients with measured FEV1 
(n<150), linearity was not assessed and adjustment for potential confounders was 
limited (Fuster et al. 2006; Lizak et al. 2009). In the current study there was a near 
linear relationship between FEV1 and both hospital stay and in-hospital mortality 
across the spectrum of lung function, and this association persisted after controlling 
for other potentially important confounders including age, sex, cardiovascular risk 
factors and socioeconomic status. 
The prevalence of airflow limitation on spirometry was much higher than that 
recorded in the clinical database, and at 15% overall was closer to the 11.8% 
prevalence for men and 8.5% prevalence for women estimated in a large 
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international cross-sectional study in individuals aged 40 and over (Buist et al. 2007). 
As  such,  the  routine  inclusion  of  FEV1 and FVC in cardiac datasets may improve 
clinical detection of COPD. Nevertheless, higher FEV1 continued to predict lower 
hospital stay and mortality even after excluding any patient with evidence of airflow 
limitation on spirometry, suggesting that higher FEV1 may is a potentially useful 
marker even amongst people with normal lung function. 
However, to justify inclusion in risk prediction tools, putative markers should also 
improve discrimination (distinguishing patients with and without adverse events) 
and/or calibration (precision of estimates of risk of adverse events) (Cook 2007). In a 
recent review of nineteen published risk prediction models the EuroSCORE was 
found  to  be  the  best  discriminator  for  30-day  and  one  year  mortality  after  cardiac  
surgery (Nilsson et al. 2006). When combined with EuroSCORE FEV1 improved 
discrimination compared to EuroSCORE alone. The area under the curve was higher, 
although the difference was not statistically significant, while the more powerful Net 
Reclassification Index was highly statistically significant, and estimated that over a 
third of patients would be assigned a more appropriate risk of in hospital death when 
FEV1 was combined with the EuroSCORE compared to the EuroSCORE alone. 
Calibration was also improved on adding FEV1 to the EuroSCORE. These findings 
are from a single centre and should be validated in an independent dataset including 
a range of surgical practices. Nevertheless, FEV1 appears to have additional value, 
beyond identifying patients with chronic lung disease, as an independent predictor of 
outcome in patients undergoing cardiac surgery. 
Moreover, FEV1 is not a costly new biomarker, but rather a widely available 
physiological measurement that is already performed in over 90% of patients 
undergoing elective and urgent cardiac surgery. FEV1 remains stable over time and 
can therefore be measured at an early stage of evaluation prior to cardiac surgery 
(Anthonisen et al. 1994). In many healthcare settings it may be possible to link 
spirometry and cardiac surgery records deterministically, using unique hospital 
numbers, at minimal cost to facilitate the development and validation of a clinical 
risk score that incorporates FEV1. Therefore, FEV1 is an attractive candidate for 
inclusion in prognostic models. 
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The mechanisms responsible for the inverse association between FEV1 and adverse 
outcomes are unknown, and have not been addressed in this study. Reductions in 
FEV1 may reflect both increased exposure and susceptibility to pro-inflammatory 
factors, such as cigarette smoking, environmental pollution and microbial infection, 
or may simply be an indicator of the patients’ capacity to withstand the insult of 
major surgery, reflecting their respiratory reserve, nutritional status or muscle 
strength. If the latter, then FEV1 may be capturing similar information to that 
obtained in the recent study by Lee et al in which questionnaire-based measures of 
frailty were found to be related to both in-hospital mortality and mid-term survival 
(Lee et al. 2010). 
2.4.1. Limitations 
The spirometry database was linked to the regional cardiac surgery database using 
non-unique shared fields, rather than a single unique identifier such as a hospital 
number. Under the agreed linkage procedures, permission was not obtained to allow 
access to medical records and so the sensitivity and specificity of the linkages could 
not  be  assessed,  and  it  is  possible  that  a  few  records  pertaining  to  different  
individuals have been inadvertently linked. However, any such mismatches would be 
likely to result in non-differential misclassification bias, underestimating the strength 
of association between FEV1 and both mortality and length of stay. All known 
prognostic markers were not recorded at the time of the matching and anonymisation, 
and therefore active endocarditis, critical pre-operative state, or post-infarct septal 
rupture were not included in the EuroSCORE calculation. However, these clinical 
variables are present in less that 0.1% of patients undergoing urgent cardiac surgery 
in this regional centre (results not shown) and similar associations for FEV1 and 
length of stay and mortality were found even when restricting the analysis to elective 
surgery, making confounding by these ‘critical illness’ variables unlikely. 
FEV1 was analysed as a continuous variable and cut-offs were not chosen in a data-
drive manner, but the discrimination and calibration for FEV1 are likely to be slight 
overestimates as these were evaluated using the same data with which the 
associations between FEV1 and length of stay and in-hospital mortality were 
identified, and the findings should be confirmed in an independent dataset. 
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2.4.2. Conclusions 
 FEV1 is a strong and independent predictor of length of stay and in-hospital 
mortality following elective and urgent cardiac surgery, and improves the 
discrimination of existing risk prediction tools. Spirometry is a widely available non-
invasive physiological measure that is already performed in of the majority of 
patients undergoing cardiac surgery. FEV1 should be included in prospective studies 
of surgical outcome, and be formally evaluated for inclusion in new cardiac surgery 
risk prediction tools. 
In the remaining chapters different mechanisms/processes linking COPD/reduced 
FEV1 and  cardiovascular  risk  are  addressed.  In  Chapters  3  and  4  the  role  of  
exacerbation of COPD is examined, and in Chapters 5, 6, and 7 the relationship 
between COPD, reduced FEV1 and emphysema and the systemic vasculature are 
examined. 
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3. Survey of respiratory consultants in Scotland: 
Opinions on the investigation of acute cardiac 
events following admission to hospital with acute 
exacerbations of chronic obstructive pulmonary 
disease 
3.1. Introduction 
Cardiovascular diseases is common in COPD (Section 1.2.1) and the risk of acute 
myocardial infarction appears to be yet higher in the period during and immediately 
following diagnosis with an acute exacerbation of chronic obstructive pulmonary 
disease (hereafter exacerbation) (Huiart et al. 2006; Donaldson et al. 2010).  
Furthermore, coronary events may present without chest pain (Canto et al. 2000), are 
missed even in simple chest pain presentations (Collinson et al. 2000) and may be 
more likely to be missed in more complex presentations, such as when patients have 
other acute illnesses, such as exacerbation of COPD.  
Although published guidelines emphasise 'extra-pulmonary manifestations' in COPD, 
they  do  not  address  whether  and  how  patients  with  exacerbations  should  be  
investigated to identify acute cardiac disease (Gold Executive Committee 2008; 
American Thoracic Society/European Respiratory Society 2004; NICE 2004). 
Therefore, the aim of this chapter is to identify whether there is clinical consensus 
amongst Scottish Respiratory Consultants regarding the investigation of patients for 
acute coronary syndrome following admission to hospital with exacerbation of 
COPD. 
3.2. Methods 
Seventy-two Scottish  Respiratory  Consultants  were  e-mailed  a  link  to  a  web-based  
survey (Figure 3-1. The survey consisted of multiple choice and Likert Scale 
questions about the investigation of chest pain in exacerbations. Items included were 
obtained from the most comprehensive systematic review examining the value and 
limitations of the chest pain history and presence of risk factors in the identification 
of patients at increased risk of acute myocardial infarction (Swap & Nagurney 2005). 
Consultants who did not respond to the first invitation were sent a second email. 
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Figure 3-1 Example question from online questionnaire 
3.3. Results 
There were 46 (64%) respondents overall, and 33 (46%) answered additional 
questions about the usefulness of the available tests. 
Two respondents screen all exacerbation patients for coronary events regardless of 
symptoms, 15 screen all those with chest pain, while 28 respondents (61%) 
investigate only selected exacerbation patients with chest pain. 
In those who investigate selected patients, the most important determinant was the 
chest pain character. COPD and exacerbation characteristics were not important 
determinants (Table 3-1). 
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Table 3-1 Self-reported determinants in respondents who reported that 
they investigate selected patients with exacerbation who complain of 
chest pain 
Determinant Respondents, n (%) 
Likely or very likely to investigate  
Radiates jaw 26 (100.0) 
Exertional 22 (84.6) 
Dull or heavy 22 (84.6) 
Arrhythmia 21 (80.8) 
Hypotensive (systolic <90) 18 (69.2) 
Previous MI 18 (69.2) 
Central 16 (61.5) 
Pressure 16 (61.5) 
Unlikely or very unlikely to investigate  
Pleuritic 24 (92.3) 
Positional 22 (84.6) 
Reproduced by palpation 16 (61.5) 
Infective Exacerbation 10 (38.5) 
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Determinant Respondents, n (%) 
Neither likely nor unlikely to investigate  
Severe COPD (FEV1<30) 19 (73.1) 
Moderate COPD (FEV1 30 to 50) 21 (80.8) 
Mild COPD (FEV1 >50) 19 (73.1) 
Complains of breathlessness 18 (69.2) 
Complains of wheeze 19 (73.1) 
Complains of cough 18 (69.2) 
Requires steroids for this exacerbation 17 (65.4) 
Requires antibiotics for this exacerbation 17 (65.4) 
Pyrexial (T>37.5) 16 (61.5) 
Hypoxic (oxygen saturation <92%) 17 (65.4) 
There was considerable heterogeneity amongst the 23 participants who answered the 
additional questions on the usefulness of serial ECG and troponin for confirming and 
excluding acute coronary syndrome in patients with acute exacerbation of COPD 
(Table 3-2).  
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Table 3-2 Perceived usefulness of serial electrocardiograms and serum 
troponin in patients with acute exacerbation of COPD 
 Usefulness of ECG Usefulness of troponin 
 To exclude To confirm To exclude To confirm 
Agree/Strongly Agree 13 (57) 17 (74) 18 (78) 14 (61) 
Neither agree nor 
disagree 3 (13) 3 (13) 3 (13) 8 (35) 
Disagree/Strongly 
Disagree 7 (30) 3 (13) 2 (9) 1 (4) 
3.4. Discussion 
The results of this survey suggest that approximately 60% of Scottish Respiratory 
Consultants investigate patients with exacerbations for the presence of myocardial 
infarction only when features of the chest pain history or the presence of 
cardiovascular risk factors suggest that there is an increased risk. 
These results were obtained using self report and the true extent to which patients 
admitted to hospital with exacerbations are investigated for the presence of acute 
coronary syndrome with troponin samples and serial electrocardiograms is unknown.  
However, these findings are likely to reflect the respondents’ views on ideal practice, 
and this differs considerably from that outlined in the recent guidance from the 
National Institute for Clinical Excellence (NICE) for patients presenting with acute 
chest pain. The NICE guidance, based largely upon the results from three systematic 
reviews and one cohort study, suggests that although features of the chest pain 
history and the presence of established risk factors do predict acute coronary 
syndrome,  they  do  so  with  poor  precision,  and  that  additional  diagnostic  testing  is  
therefore needed when acute coronary syndrome is suspected (NICE 2010). 
However, like acute coronary syndrome, exacerbation is itself a recognised cause of 
chest tightness and shortness of breath (Gold Executive Committee 2008), and raised 
troponin in the presence of normal coronary angiography has been described in 
patients with exacerbation (Mahajan et al. 2006). As such, patients with exacerbation 
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may be at risk of both under-diagnosis and over-diagnosis of acute coronary 
syndrome. 
Fewer participants answered additional questions on the usefulness of ECGs and 
troponin in excluding or confirming acute coronary syndrome in the context of acute 
exacerbation of COPD. Nevertheless, there was considerable heterogeneity among 
those who did. This variability among responding clinicians may reflect the lack of 
studies examining serial ECG changes and raised troponin in the published literature. 
3.4.1. Conclusion  
There was no clear clinical consensus regarding the investigation of acute coronary 
syndrome  in  this  survey,  and  patients  with  exacerbations  are  at  theoretical  risk  of  
both under-diagnosis and over-diagnosis. As such, further research is justified to 
address this clinical problem. Since the prevalence of acute coronary syndrome in 
exacerbations is unknown, the prevalence of chest pain, serial electrocardiogram 
changes, and serum troponin were subsequently studied in a case-series of patients 
with exacerbations (Chapter 4). 
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4. Case series of patients with acute exacerbation of 
COPD: prevalence of chest pain, electrocardiogram 
changes, and raised troponin 
4.1. Introduction 
Coronary heart disease is a major cause of death in COPD (Section 1.2.1), both 
conditions share common risk factors, and reduced FEV1, a characteristics feature of 
COPD, is an independent risk factor for cardiovascular morbidity and mortality 
(Section 1.2.3). 
Evidence from healthcare utilisation data suggest that the risk of myocardial 
infarction may be further increased during exacerbations in patients with COPD 
(Huiart et al. 2006; Donaldson et al. 2010), while raised troponin has been found to 
be associated with increased mortality in exacerbation of COPD (Baillard et al. 2003; 
Brekke, Omland, Holmedal, et al. 2008). When troponin was measured in a 
consecutive sample of 71 patients with severe exacerbation of COPD, the in-hospital 
mortality  was  considerably  higher  when  troponin  was  raised  compared  to  when  
troponin was not raised, with 8 deaths (62% mortality) and 10 deaths (17% 
mortality) respectively (Baillard et al. 2003). Moreover, raised CRP, Il-6, fibrinogen 
and increased platelet activation have been reported in exacerbations of COPD, 
compared to the stable state, (Wedzicha et al. 2000; Hurst et al. 2006; Maclay, 
McAllister, Mills, Newby, et al. 2009) and inflammation is implicated in plaque 
rupture and thrombus formation. (Libby 2002). 
One retrospective case-note review has examined the prevalence of raised troponin in 
patients admitted to hospital with exacerbation of COPD (Harvey & Hancox 2004) 
but no prospective study has systematically investigated patients admitted to hospital 
with exacerbations of COPD for evidence of acute coronary syndrome. 
Therefore, the aim of this chapter is to identify the prevalence of acute coronary 
syndrome in patients admitted to hospital with exacerbations of COPD in a 
prospective a case-series. 
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4.2. Methods 
Patients were recruited at 4 hospitals in Central Scotland, Edinburgh Royal 
Infirmary, The Royal Infirmary of Glasgow, Monklands District General Hospital 
and Crosshouse District General Hospital. At each site the local investigator 
recruited patients from accident and emergency and acute medical (admission) units. 
Patients aged 40 or older, diagnosed as having an acute exacerbation of COPD by a 
medical or respiratory consultant physician, and with a ten or more pack year history 
of cigarette smoking were recruited. Patients were excluded if the primary presenting 
complaint was chest pain, more than 48 hours had elapsed since admission, an 
alternative diagnosis was suggested by the admission chest x-ray, or pulmonary 
embolism was confirmed on computed tomography pulmonary angiography. 
Acute coronary syndrome is defined as raised troponin in the presence of a consistent 
clinical history (Alpert et al. 2000). However, exacerbation of COPD might plausibly 
cause raised troponin independently of coronary disease (Mahajan et al. 2006). 
Therefore, a priori, acute coronary syndrome during acute exacerbation of COPD 
was defined as raised troponin, chest pain, and indicative serial electrocardiogram 
(ECG) changes. 
A detailed chest pain and exacerbation history was completed, and recorded on a 
standard form (Figure 4-1). The details from the form were later entered onto an 
online form with validation at each centre. If an admission ECG had been performed 
then this was obtained. If not, an admission ECG was performed by the investigator, 
provided this could be done within 24 hours of admission. A second ECG was 
performed between 12 and 36 hours after the initial ECG. Where one or more ECG 
obtained prior to the admission was available a copy was obtained. A non-fasting 
blood sample was taken and each local hospital laboratory measured serum troponin, 
High Density Lipoprotein (HDL) and total cholesterol, triglycerides, full blood 
count, and CRP. Where patients reported chest pain, the sample was taken not less 
than 12 hours after the most recent episode, otherwise troponin was measured not 
less than 12 hours following admission. Spirometry results were either obtained from 
the patient’s case notes, or from the local lung function service. Research Ethics 
Committee Approval was obtained and patient consent was obtained for all study 
protocols and procedures (06/MRE10/78). 
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Figure 4-1 Data collection form 
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Toponin I (Abbott Architect, Illinois, USA) was measured in Edinburgh Royal 
Infirmary,  The  Royal  Infirmary  of  Glasgow,  and  Troponin  T  (Roche,  Basle,  
Switzerland) was measured in Monklands and Crosshouse District General 
Hospitals. The American College of Cardiology/European Society of Cardiology 
(ACC/ESC) joint guidelines for the definition of myocardial infarction recommend 
using the 99th percentile of the normal reference population to define raised 
troponin, and that the assay should achieve a co-efficient of variation of  10% (10% 
CV) at the 99th percentile value (Alpert et al. 2000). However, until recently, no 
troponin assay could achieve this level of precision, and therefore the 
recommendation  of  Apple  et  al  to  define  the  cut-off  as  the  10%  CV  level  was  
followed, as was the recommendation to express the magnitude of elevation in 
troponin as multiples of the 10% CV level (Apple et al. 2002). 
All ECGs were coded using the Minnesota Code (Prineas 1982). A single reader 
(David McAllister) coded all ECGs blinded to all clinical features, blood results and 
whether the ECG was the first or second ECG following admission, or an ECG 
obtained prior to admission. In 48 ECGs collected at the Glasgow site Minnesota 
codes were also identified electronically. Agreement for electronic and paper reads 
for the presence/absence of Q-waves, ST depression and T wave flattening/inversion 
was calculated (Kappa=0.73, 0.61 and 0.57 respectively). Serial ECG changes 
indicative of an acute cardiac event were defined using the Minnesota code criteria 
for independently read serial ECGs (Prineas 1982, p.204). All ECGs were 
additionally coded using the Cardiac Injury Infarction Score under the same 
conditions (Rautaharju et al. 1981). 
Although the occurrence of acute coronary syndrome in the absence of chest pain is 
well  documented  (Canto  et  al.  2000),  certain  features  of  the  chest  pain  history  are  
recognised as being indicative of a higher risk of an ischaemic event (pain which is 
“like a pressure”, radiates to either shoulder or arm, or is related to exertion) while 
others are indicative of a reduced risk of an ischaemic event (pleuritic, related to 
movement, reproduced by palpation, sharp or of very short or long duration (<2 min 
or >12 hours) (Swap & Nagurney 2005). On this basis chest pain was categorised as 
high risk if only high risk features were present in the history, low risk if only low 
risk features were present in the history, both if a combination of both high and low 
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risk features were present, or indeterminate in neither high nor low risk features were 
present. 
The prevalence of chest pain, raised troponin and serial ECG changes was calculated 
along with 95% confidence intervals, using the Score test for small samples where 
the prevalence was <0.10. In exploratory analyses, associations between patient 
characteristics and raised troponin were examined using Fisher’s exact test, for 
which all associations where the p-value was <0.10 are reported. Analyses were 
performed using SAS version 9.2 (Cary, North Carolina, USA) and R version 2.9.2 
(Vienna, Austria). 
4.3. Results 
A total of 242 patients were recruited, 143 from Edinburgh Royal Infirmary, 48 from 
the Royal Infirmary of Glasgow, 42 from Monklands District General Hospital and 9 
from Crosshouse District General Hospital. The mean (SD) age was 69 (9), 108 
(45%) were male and almost half were current smokers, with the majority having 
severe or very severe airflow limitation on spirometry (Table 4-1). All patients were 
breathless on admission, increased sputum volume was present in 130 (54%) and 
sputum purulence in 141 (58%), leukocytosis in 113 (47%) and raised CRP (>6 
mg/dL) in 158 (74%). All were treated with nebulised bronchodilators, 217 (90%) 
with oral prednisolone, and 164 (68%) with antibiotics. The median (IQR) length of 
stay was 5 (3-8) days and 21 (15%) of the 143 patients at the Lothian site died within 
12 months of admission. 
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Table 4-1 Patient characteristics 
n 242 
Stable characteristics  
Age, years, mean (SD) 69 (9) 
Male Gender, n (%) 108 (45%) 
Height, metres, mean (SD) 1.62 (0.10) 
Current Smoker, n (%) 115 (48%) 
Pack Years, median (IQR) 50 (33-63) 
 FEV1, litres, median (IQR) 0.90 (0.68-1.20) 
FVC, litres, median (IQR) 2.05 (1.63-2.65) 
 FEV1/FVC ratio, median (IQR) 44 (35-55) 










Performance status  3, n (%) 73 (31%) 
Long term oxygen therapy, n (%) 40 (17%) 
Home Nebulisers, n (%) 119 (49%) 
Long-acting beta agonists, n (%) 172 (71%) 
Long-acting anticholinergics, n (%) 120 (50%) 
Methylxanthines, n (%) 34 (14%) 
Inhaled corticosteroid, n (%) 195 (81%) 
Long term oral steroids, n (%) 6 (2%) 
  78 
n 242 
Exacerbation characteristics  
MRC Dyspnoea Score  4, n (%) 216 (92%) 
Heart rate, mean (SD) 102 (20) 
Respiratory Rate, mean (SD) 24 (5) 
Systolic BP, mean (SD) 135 (25) 
Diastolic BP, mean (SD) 73 (16) 
Arterial blood gases, mean (SD)  
Hydrogen 41 (8) 
PaO2 11 (4) 
PaCO2 6 (2) 








Leukocytosis (WCC >11) 113 (47%) 
Raised CRP (>6 mg/dl), n (%) 158 (74%) 
Haemoglobin, g/dl, mean (SD) 135 (18) 
Prescribed antibiotics, n (%) 164 (68%) 
Prescribed oral prednisolone, n (%) 217 (90%) 
Treated with non-invasive ventilation 15 (6%) 
Length of stay, median (IQR) 5 (3-8) 
12 month mortality (Lothian), n (%) 21 (15%) 
The patients were similar to those recruited in the 2008 British Thoracic Society 
Audit of patients admitted to hospital with acute exacerbation of COPD (Table 4-2). 
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Table 4-2 Comparison of patient characteristics for this case-series with 
those from the BTS COPD Audit 2008 
 Case series BTS Audit 
Age, mean, years 69 73 
Male sex, % 45% 50% 
Length stay, median, days 5 5 
Height, median, m 1.62 1.64 
 FEV1 percent predicted, median 43% 38% 
Current smoker, % 48% 33% 
MRC 4-5 prior admission, % 65% 67% 
Systemic steroids within 24h, % 90% 86% 
Antibiotics within 24h, % 68% 81% 
Acidotic on admission, % 21% 20% 
Non-invasive ventilation, % 6% 11% 
Sputum vol increased, % 54% 66% 
Sputum purulence increased, % 58% 61% 
Albumin g/dl, median 39 39 
Creatinine, mmol/l, median 83 83 
Ischaemic heart disease, % 32% 25% 
Stroke, % 10% 6% 
Diabetes, % 12% 12% 
Cardiovascular risk factors were common (Table 4-3). Over 30% had a past medical 
history of ischaemic heart disease, 34 (14%) had previous stroke or peripheral 
vascular disease, with 101 (42%) having vascular disease at any site. Hypertension 
and hypercholesterolaemia were also common. Non-fasting HDL cholesterol and 
cholesterol:HDL ratio were 1.73 (0.61) mmol/l and 2.97 (1.07) respectively. 
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Amongst the 141 patients without known vascular disease 19 (13%) had an estimated 
(Framingham) risk of a cardiac event within 10 years of 20% or greater (Expert 
Panel  on  Detection,  and  Treatment  of  High  Blood  Cholesterol  in  Adults  (Adult  
Treatment Panel III) 2001). Around one third of patients were on regular statin 
therapy, and 96 (40%) were on antiplatelet therapy, although only 5 (2%) were on a 
beta-blocker. 
Table 4-3 Cardiovascular risk factors and therapy 
n 242 
IHD, n (%) 
None 
Diagnosed by generalist 







Stroke or peripheral vascular disease, n (%) 34 (14%) 
Hypertension, n (%) 90 (37%) 
Hypercholesterolaemia, n (%) 76 (31%) 
Diabetes, n (%) 30 (12%) 
Family History of IHD, n (%) 76 (31%) 
Creatinine >120 mmHg, n (%) 24 (10%) 
Non-fasting lipids, mean (SD)  
HDL Cholesterol, mmol/l 1.73 (0.61) 
Cholesterol:HDL Ratio 2.97 (1.07) 
Triglycerides, mmol/l 1.45 (0.87) 
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n 242 
Nitrate or nicorandil, n (%) 35 (14%) 
Calcium channel blocker, n (%) 38 (16%) 
Beta blocker, n (%) 5 (2%) 
ACE-inhibitor/ AR2Blocker, n (%) 44 (18%) 
Diuretic, n (%) 82 (34%) 
Statin therapy, n (%) 85 (35%) 
Antiplatelet therapy, n (%) 96 (40%) 
Antidiabetic therapy, n (%) 13 (5%) 
*Confirmed IHD refers to ischaemic heart disease confirmed through diagnostic 
exercise tolerance testing, angiography, or proven myocardial infarction. 
Chest pain was also common, with 124 (51%; 95% CI 48 to 58%) patients reporting 
chest pain, which was most commonly tight or sharp, but was frequently related to 
exertion (Table 4-4). 
  82 
Table 4-4 Chest pain 
Characteristics n (%) 
Duration <2 min or >12 hours† 87 (82%) 
Central 76 (61%) 






Dull 12 (10%) 
Like a pressure* 11 (9%) 
Heavy 4 (3%) 
Burning 1 (2%) 
Gripping 2 (2%) 
Autonomic symptoms (volunteered) 8 (6%) 
Precipitating factors  
Exertion* 62 (52%) 
Exertion, but pain also present at rest 44 (36%) 
Deep inspiration† 7 (6%) 
Coughing 20 (16%) 
Palpation (pain reproduced) † 11 (9%) 
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Characteristics n (%) 
Relieving factors (partial or complete)  
Nitrate therapy 18 (15%) 
Bronchodilator therapy 15 (12%) 
Oxygen therapy 13 (10%) 
Had similar pain previously  
During an exacerbation 67 (54%) 
When stable 31 (25%) 
Summary of chest pain  
High risk features only 50 (40%) 
Low risk features only 21 (17%) 
Low and high risk features 22 (18%) 
Neither low nor high risk features 31 (25%) 
† Chest pain features associated with low risk, *chest pain features associated with 
high risk 
Sinus tachycardia was the commonest abnormality on admission ECG and was found 
in 112 (46%) patients. Fourteen (6%) patients had atrial fibrillation, 15 (6%) had 
right bundle branch block with 12 (5%) having left bundle branch block. Twenty 
(8%) had p-pulmonale. Diagnostic Q-waves and T-wave inversion were common (34 
(14%) and 37 (15%) patients respectively), and the mean (SD) cardiac injury 
infarction score was 16 (10). Eighteen (7.5%) patients had no ECG within the first 24 
hours of admission, while 21 (8.6%) had no second ECG. Only 3 patients developed 
Q-waves during admission, although serial changes in T-wave inversion/flattening 
and ST depression were common (65 (32%) and 19 (9%) respectively). Thirteen 
(6%) had serial changes in ST elevation (Table 4-5). 
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Table 4-5 Characteristics of first admission ECG and serial changes 
Initial ECG N 242 
 Conduction defects  
 First degree block (63) 1 (0.4%) 
 Incomplete RBBB (73) 10 (4%) 
 Complete RBBB (721) 5 (2%) 
 Incomplete LBBB (76) 8 (3%) 
 Complete LBBB (711) 4 (2%) 
 Arrhythmias  
 Sinus tachycardia (87) 112 (46%) 
 Premature atrial/junctional beats (811,813) 17 (7%) 
 Premature ventricular beats (812, 813) 6 (2%) 
 Atrial fibrillation (831 or 833) 14 (6%) 
 Wandering atrial pacemaker (814) 1 (0.4%) 
 Other  
 p-pulmonale (93) 20 (8%) 
 Low QRS amplitude (91) 3 (1%) 
 Diagnostic Q waves (D1) 34 (14%) 
 Equivocal Q waves (E1) 20 (8%) 
 ST elevation with T-wave inversion (D2) 2 (0.8%) 
 ST depression (E2) 32 (13%) 
 T waves inverted or flat (E3) 58 (24%) 
 ST elevation without T wave inversion (E4) 7 (3%) 
 Cardiac Injury Infarction Score, mean (SD) 16 (10) 
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Serial change N 203 
 Major Q-waves 3 (1.5%) 
 T-wave inversion/flattening 65 (32%) 
 ST depression 19 (9%) 
 ST elevation 13 (6%) 
 Cardiac Injury Infarction Score, mean (SD) -1 (9) 
Twenty-four (10%) patients had elevated serum troponin, with 22 (9%) patients 
having a level greater than twice the cut-off and 15 (6%) having a serum troponin 
level greater than three times the cut-off. Of those with raised troponin, 11 had serial 
ECG changes (new Q waves or serial changes in T-waves or ST segments), and 13 
had  chest  pain.  Six  patients  had  chest  pain,  ECG  changes  and  raised  troponin.  As  
such, by the a priori definition, the prevalence of acute cardiac events was 2.5% 
(95% CI 1.0 to 5.6%, Table 4-6). 
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Table 4-6 Chest pain and ECG changes in each patient with raised 
troponin 
 ECG Summary Chest pain 
 Troponin >1 x lower limit of 
detection 
 
- Inverted T waves, no repeat ECG None 
- No ischaemic features Tight 
 Troponin >2 x lower limit of 
detection 
 
- Diagnostic Q waves and serial T wave 
changes 
Central, lasting less than 2 minutes 
- Diagnostic Q waves and serial T wave 
changes 
Tight, pleuritic 
- Serial ST elevation, without serial T 
wave changes 
None 
- Serial T wave changes None 
- Diagnostic Q waves None 
- No ischaemic features Central, tight, relieved by 
bronchodilators/oxygen 
- No ischaemic features None 
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 ECG Summary Chest pain 
 Troponin >3 x lower limit of 
detection 
 
- New diagnostic Q waves, and serial T 
wave changes 
Central, sharp 
- Serial ST depression Tight, lasting less than 2 min, 
exertional, radiating to arm/jaw 
- Serial ST depression None 
- Diagnostic Q waves and serial T wave 
changes 
None 
- Diagnostic Q waves and serial T wave 
changes 
None 
- Serial T wave changes Upper chest pain, worse on movement, 
relieved partly by oxygen 
- Serial T wave changes None 
- Diagnostic Q waves, and inverted T 
waves on first ECG 
None 
- Diagnostic Q waves Central 
- No ischaemic features Central, sharp, lasted >12 hours, 
exertional 
- No ischaemic features None 
- No ischaemic features Central, tight, exertional 
- No ischaemic features Central, tight 
- No ischaemic features Central, tight, exertional, radiating to 
arm/jaw 
- No ischaemic features, no admission 
ECG 
Sharp, exertional, relieved partly by 
oxygen 
However, neither chest pain, nor chest pain with exclusively high risk features, was 
associated with raised troponin (p=0.77 and p=0.29 respectively). Raised troponin 
was commoner in patients with admission ECGs with diagnostic Minnesota codes for 
myocardial infarction (p=0.06) but there was no evidence that serial ECG changes 
were commoner and (p=0.39). 
In exploratory analyses the associations between raised troponin and a wide range of 
patient characteristics were examined, including severity of airflow limitation, 
performance status, smoking status, usual and acute therapy, anaemia, raised 
inflammatory markers and symptoms suggestive of infection, and arterial blood 
gases. There was some evidence that diabetes, right bundle branch block, acidosis 
and methylxanthine therapy in patients with exacerbations may be associated with 
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raised troponin, while use of a long acting beta-agonist was less common in patients 
with raised troponin (Table 4-7). 
Table 4-7 Raised troponin relative to chest pain, ECG features and 
selected characteristics 
 >3 x LLD >1 x LLD  LLD p-Value 
Chest pain     
Any 9 (60%) 4 (44%) 111 (51%) 0.77 
High risk 2 (13%) 0 (0%) 48 (22%) 0.29 
New pain 6 (40%) 4 (44%) 84 (31%) 0.94 
First admission ECG     
Diagnostic ECG 4 (27%) 3 (33%) 28 (13%) 0.06 
Equivocal ECG 5 (33%) 3 (33%) 80 (36%) >0.99 
Sinus tachycardia 8 (53%) 7 (78%) 97 (44%) 0.14 
Left bundle block 0 (0%) 0 (0%) 12 (6%) >0.99 
Right bundle block 3 (20%) 0 (0%) 12 (6%) 0.08 
p-Pulmonale 2 (13%) 1 (11%) 17 (8%) 0.36 
Right axis deviation 2 (13%) 1 (11%) 17 (8%) 0.36 
CIIS, mean (95%CI) 20 (16-25) 17 (10-23) 15 (14-17) 0.13 
Serial ECG changes 7 (50%) 4 (50%) 72 (40%) 0.39 
CIIS, mean (95%CI) 1 (-3-6) 4 (-1-10) -2 (-3-0) 0.11 
Airflow limitation     
Mild 2 (20%) 0 (0%) 8 (5%)  
Moderate 2 (20%) 1 (20%) 56 (33%)  
Severe 5 (50%) 1 (20%) 59 (35%)  
Very severe 1 (10%) 3 (60%) 48 (28%) 0.19 
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 >3 x LLD >1 x LLD  LLD p-Value 
Performance Status (PS) 
when stable 
    
PS 0 2 (14%) 0 (0%) 9 (4%)  
PS 1 4 (29%) 1 (13%) 60 (28%)  
PS 2 4 (29%) 2 (25%) 84 (39%) 0.40 
PS 3 3 (21%) 4 (50%) 50 (23%)  
PS 4 1 (7%) 1 (13%) 14 (6%)  
Long term oxygen 1 (7%) 1 (11%) 38 (17%) 0.67 
Current smoker 7 (47%) 3 (33%) 105 (48%) 0.71 
Diabetes 5 (33%) 1 (11%) 24 (11%) 0.05 
Long acting beta agonists 7 (47%) 5 (56%) 160 (73%) 0.05 
Methylxanthines 5 (33%) 4 (44%) 25 (11%) 0.002 
Medical Research Council 
dyspnoea score (MRC) on 
admission 
    
MRC 1 0 (0%) 0 (0%) 1 (0%)  
MRC 2 0 (0%) 0 (0%) 3 (1%)  
MRC 3 2 (15%) 1 (11%) 12 (6%) 0.41 
MRC 4 1 (8%) 0 (0%) 41 (19%)  
MRC 5 10 (77%) 8 (89%) 156 (73%)  
Arterial blood gases     
Acidosis 5 (33%) 3 (33%) 33 (15%) 0.04 
Hypoxia 3 (20%) 1 (11%) 75 (34%) 0.24 
Hypercapnia 5 (33%) 6 (67%) 95 (44%) 0.43 
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4.4. Discussion 
One in ten patients admitted to hospital with an acute exacerbation of COPD had 
raised  troponin,  and  a  quarter  of  these  also  had  chest  pain  and  serial  
electrocardiogram changes indicative of acute coronary syndrome. 
Previous studies found that raised troponin was common in exacerbation of COPD. 
In one consecutive case-series of 71 patients admitted with acute exacerbation of 
COPD 13 (18% (95% CI 11 to 29%) had raised troponin, (Baillard et al. 2003) and in 
a case note review of 375 patients admitted to hospital with COPD, troponin was 
raised in 24% (95% CI 19 to 31%) of those in whom it was measured. The former 
study was conducted in an intensive care setting, and in the latter troponin was 
measured in only half the sample, with those tested having been selected non-
randomly by the treating clinician. The current case series did not consecutively 
recruit all admitted patients, but the sample was nonetheless very similar to that 
obtained in the recent BTS 2008 audit which did sample consecutive patients 
admitted to hospital with acute exacerbation of COPD (Table 4-2). Therefore, this 
case-series adds to the literature by confirming that raised troponin is common in 
patients admitted to hospital with exacerbation of COPD not selected for troponin 
testing on clinical grounds. 
A priori acute coronary syndrome was defined as raised troponin, serial ECG 
changes indicative of ischaemia, and chest pain. One in forty patients with acute 
exacerbation of COPD met this definition, whereas in a previous study in patients 
with exacerbation of COPD, Donaldson et al estimated the prevalence as 1 in 2,500 
(Donaldson et al. 2010). The previous study examined patients treated in the 
community whereas this was an in-patient study, which may partly account for the 
higher prevalence. However, there were also differences in the investigation and 
diagnosis of acute coronary syndrome. Donaldson et al used routine healthcare data 
whereas this prospective case-series obtained chest pain histories and serial ECGs on 
the entire sample. Coronary events can be missed even when patients present with 
chest pain (Collinson et al. 2000) and may be more likely to be missed when patients 
present  to  hospital  with  an  alternative  condition,  such  as  exacerbation  of  COPD.  
None of the patients identified as having acute coronary syndrome were prescribed 
thrombolytic agents or high dose low molecular weight heparin suggesting that the 
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treating clinicians did not suspect acute coronary syndrome. As such, acute coronary 
syndrome may be under-diagnosed in patients with exacerbation of COPD.  
Alternatively, raised troponin, chest pain and serial ECG changes may be less 
reliable for diagnosing acute coronary syndrome in the context of exacerbation of 
COPD. Cardiac troponin is a sensitive and specific marker of myocardial damage, 
but it is not pathognomonic for acute coronary disease (Christenson et al., with Wu et 
al., NACB WRITING GROUP MEMBERS and Jesse et al., NACB COMMITTEE 
MEMBERS 2007), and has been described following pulmonary embolism, 
supraventricular and ventricular tachycardia and non-cardiac surgery in patients with 
normal coronary arteries on angiography (Mahajan et al. 2006). Pathophysiological 
changes during exacerbation such as reduced right ventricular preload and increased 
afterload may also cause myocardial damage (O’Donnell & Parker 2006). Similarly, 
hypoxia, acidosis or tachycardia, all of which are found in exacerbations of COPD, 
might cause myocardial cell death, and raised troponin was commoner in patients 
with acidosis and right bundle branch block, a finding which replicated a previous 
report from a case note review of patients with exacerbation of COPD (Harvey & 
Hancox 2004) 
Previous authors have suggested that central chest pain typical of myocardial 
infarction is rare in exacerbation of COPD (Donaldson et al. 2010), but recent chest 
pain was surprisingly common in this case series, frequently exertional, and 
occasionally radiated to the jaw. Moreover, neither chest pain, nor chest pain with 
features typically considered to be suggestive of cardiac ischaemia (Swap & 
Nagurney 2005) was associated with raised troponin. Chest pain character is only of 
limited prognostic value in uncomplicated chest pain (NICE 2010), and these 
findings suggest it may be even less useful in patients with exacerbation of COPD. 
Electrocardiogram abnormalities such as Q-waves on the admission ECG were also 
common, a finding which is consistent with previous work demonstrating that ECG 
findings which predict long-term risk of myocardial infarction are commonly raised 
in patients hospitalised with acute exacerbation of COPD (Brekke, Omland, Smith, et 
al. 2008), as well as being  associated with reduced FEV1 (Sin & Man 2003). 
Changes in T-waves and in ST segment depression across serial ECGs were also 
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common. However, serial ECG changes were not associated with raised troponin in 
this case-series, suggesting that technical factors (eg lead position) or transient 
ischaemia may cause a significant proportion of serial ECG abnormalities in 
exacerbation of COPD. 
However, 50% of patients in the sample either had known vascular disease or an 
estimated 10 year (Framingham) risk of a cardiac event of greater than 20%, patients 
with  COPD  are  known  to  have  an  elevated  risk  of  cardiovascular  mortality  and  
morbidity (McGarvey et al. 2007; Anthonisen et al. 2002) and two previous 
observational studies using routine healthcare data found that the risk of myocardial 
infarction was two-fold higher in patients with COPD during and immediately 
following acute exacerbations (Huiart et al. 2006; Donaldson et al. 2010). 
Furthermore, inflammation has been implicated in plaque rupture and thrombus 
formation  (Libby 2002),  and  exacerbation  of  COPD is  associated  with  raised  CRP,  
Il-6 and fibrinogen, (Wedzicha et al. 2000; Hurst et al. 2006) while in a recent study 
conducted in a sub-group of patients from this case-series that has been reported in 
abstract form, platelet activation was higher during exacerbations than in the stable 
state (Maclay, McAllister, Mills, Newby, et al. 2009). 
Therefore, although non-coronary mechanisms such as right heart strain and acidosis 
may cause the majority of cases of raised troponin in exacerbation of COPD, 
coronary mechanisms are also implicated. As such, the high prevalence in 
exacerbation of COPD of raised troponin, chest pain conventionally considered 
suggestive of ischaemia, and abnormal ECGs represent a diagnostic difficulty. 
Larger observational studies may identify further patient characteristics which are 
associated  with  raised  troponin,  but  are  unlikely  to  identify  whether  these  are  also  
indicative of acute coronary artery thrombosis. Indeed, given the clinical complexity 
only  experimental  studies  (eg  clinical  trials  of  secondary  prevention  strategies)  are  
likely  to  address  the  question  of  how best  to  manage  patients  with  exacerbation  of  
COPD and raised troponin. 
4.4.1. Limitations 
This was not a consecutive sample of patients admitted with acute exacerbation of 
COPD, limiting generalisability to other populations. However, this case-series 
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included patients from district general as well as teaching hospitals, and this sample 
are similar to the consecutive sample described in the 2008 British Thoracic Society 
audit of patients admitted to hospital with acute exacerbation of COPD (Buckingham 
et al. 2008). Moreover, patients were not sampled on the basis of chest pain, troponin 
or ECG changes making systematic bias less likely. 
The troponin measurements were conducted in different laboratories using different 
assays rather than a single centre. However, studying patients across multiple centres 
was a strength of the study, a recommended method for summarising the results 
across multi-centre studies was employed, and results were not directly compared 
between centres (Apple et al. 2002). 
A further limitation was that the ECGs were obtained as part of routine clinical care, 
in patients who were frequently acutely unwell, rather than in controlled conditions. 
As such, the accuracy of the coding is likely to have been reduced, particularly when 
evaluating the degree of ST segment changes. However, this also meant that the 
ECGs were representative of those encountered by clinicians treating this patient 
group. 
4.4.2. Conclusion 
Raised troponin is common in patients with exacerbation of COPD, as is chest pain 
and serial changes in electrocardiograms. Identifying whether patients admitted to 
hospital with acute exacerbation of COPD have had an acute coronary event is 
difficult as both chest pain and serial electrocardiogram changes are commonly 
found in patients without raised troponin. Experimental studies are needed to address 
the question of how to manage raised troponin in acute exacerbation of COPD. 
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5. Cross-sectional study in patients with chronic 
obstructive pulmonary disease: carotid-radial pulse 
wave velocity 
5.1. Introduction 
Cardiovascular disease is a common cause of death in patients with Chronic 
Obstructive  Pulmonary  Disease  (COPD)  (Anthonisen  et  al.  2002;  McGarvey  et  al.  
2007). Moreover, airflow limitation, as measured by FEV1 predicts cardiovascular 
mortality even after adjusting for established cardiovascular risk factors including 
age, sex, smoking, cholesterol, and socioeconomic deprivation (Hole et al. 1996; 
Friedman et al. 1976). 
Arterial stiffness is a useful non-invasive measure of vascular function, and is an 
independent predictor of cardiovascular events in subjects with diabetes in the 
general population (Laurent et al., on behalf of the European Network for Non-
invasive Investigation of Large Arteries 2006). Arterial stiffness is associated with 
airflow limitation in healthy men (Bolton et al. 2009; Zieman et al. 2005), and has 
been found to be higher in COPD patients compared to controls matched on age, and 
sex (Sabit et al. 2007) and in male ex-smokers with COPD compared to controls 
matched on age, pack years smoking (Maclay, McAllister, Mills, Paterson, et al. 
2009). 
The mechanism by which arterial stiffness is increased in patients with COPD is 
unknown. One hypothesis is that impaired lung function and increased arterial 
stiffness in COPD may both be due to increased susceptibility to degradation of 
connective tissue in this group of patients. In the lung, elastin degradation leads to 
loss of alveolar attachments, decreased compliance, and emphysema (Shifren & 
Mecham 2006). While in the arteries, age-related elastin degradation is associated 
with increased collagen, larger thicker arteries, and increased arterial stiffness 
(Zieman et al. 2005). 
Therefore, the aim of this chapter is to test the hypothesis that the extent of arterial 
stiffness is associated with the severity of emphysema in patients with COPD.  
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5.2. Methods 
5.2.1. Patients studied 
Patients with COPD were recruited from primary and secondary care. Blood pressure 
and arterial stiffness were measured in 177 subjects with COPD who participated in a 
cohort study designed to identify prognostic markers in COPD. During recruitment, 
ethical approval was obtained to perform high resolution computed tomography (CT) 
scans of chest. All subsequently enrolled subjects (n=73) subjects had CT scans. All 
studies were approved by Lothian Regional Ethics Committee approval, and all 
subjects gave written informed consent. 
All subjects had a clinical history compatible with COPD, a history of risk factors 
(history of at least ten pack years of smoking) and evidence of chronic airflow 
limitation on spirometry (post bronchodilator FEV1/FVC <0.70)(23). Subjects were 
not taking oral anti inflammatory drugs, including corticosteroids. Subjects with 
systemic inflammatory diseases (e.g. rheumatoid arthritis, inflammatory bowel 
disease) were excluded. Cardiovascular co-morbidity was not an exclusion criterion 
but  was  recorded.  Visits  were  performed  when  subjects  were  clinically  stable  (  4  
weeks since last exacerbation as defined by a worsening of symptoms requiring 
intervention with antibiotic therapy or oral corticosteroids). 
Height, weight, and post-bronchodilator spirometry were measured (Vitalograph 
Alpha Spirometer, Buckingham, England) according to ATS/ERS standards in all 
subjects (Miller et al. 2005). Venous blood was sampled and stored at -80 Celsius for 
subsequent analysis. Serum CRP concentrations were measured using a highly 
sensitive immunonephelometric assay (Behring BN II nephelometer, Marburg, 
Germany). Glucose and cholesterol were measured in the locally accredited clinical 
biochemistry laboratory (Olympus Analyzers, Centre Valley, USA). Oxygen 
saturations were measured at rest breathing air, by pulse oximetry (Nellcor Puritan 
Bennett Sensor, Pleasanton, USA). Individuals who underwent CT also had six 
minute walking tests in accordance with ATS guidelines (American Thoracic Society 
2002). 
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5.2.2. Haemodynamic studies 
Arterial stiffness and peripheral blood pressure measurements were obtained prior to 
spirometry and venepuncture in a quiet, temperature controlled room with subjects 
resting supine at 15 degrees. Patients had abstained from smoking, caffeine, and all 
medication on the day of the test. Systolic and diastolic blood pressure was measured 
in duplicate using an automated non-invasive oscillometric sphygmomanometer 
(Omron 705IT, Milton Keynes, UK) following a 10 min rest period. 
After 30 minutes of rest, arterial stiffness was measured using carotid-radial Pulse 
Wave Velocity (PWV) by specifically trained staff. PWV measures the rate at which 
the systolic pressure wave travels to the peripheral vasculature (Section 1.4.2). Faster 
wave transit times reflect stiffer arteries. In this study the q-wave of a simultaneously 
recorded ECG was used to identify the onset of the pressure wave, and used 
applanation tonometry (Millar Instruments, Texas) at the carotid and radial arteries to 
record  the  pressure  waveform  at  the  peripheral  site.  The  SphygmoCor™  system  
(AtCor Medical, Sydney) software applied an intersecting tangent algorithm to 
identify the onset of the wave. The difference in wave transit time between the 
carotid and radial sites was used to calculate the carotid-radial PWV. 
Quality control checks were made for all measurements according to manufacturer 
guidelines (Atcor Medical 2008). All waveforms were reviewed, as were summary 
statistics for variability between waveforms. Results with a standard deviation of 
15% or greater were not included in the analysis, nor were measurements with a 
standard deviation of 10% to 15% in which the onset of the waveform was not 
clearly identified. Where a patient had two or more measures which met QC criteria 
the mean was used. 
5.2.3. CT imaging 
High Resolution CT (CT) scanning of the lungs was performed at full inspiration 
using a 16 slice multidetector-row CT scanner (135kv, 20mAs, Toshiba Aquilion, 
Toshiba, Japan).  Patients were coached to perform full inspiration. Contrast media 
was not administered.   Images were reconstructed with a slice thickness of 5mm and 
2.5mm increment using an FC-03 filter.  Calibration of air CT density measurements 
was  made  using  a  background  air  region  above  the  sternum.   Emphysema  was  
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quantified by in house software. Percent emphysema, also known as the pixel index 
or density mask, was defined as the total number of voxels with a density of less than 
-910 Hounsfield Units (Hu) divided by to the total number of voxels in the lung 
fields (27-29). Percent emphysema at -950 (Hu) and the 15th percentile point of 
frequency distribution of lung density were also calculated. 
5.2.4. Data analysis 
A  univariate  analysis  of  carotid-radial  PWV  on  all  variables  of  interest  was  
performed  in  the  sub-group  who  had  CT  of  chest  (Pearson’s  correlation  and  
independent sample t-tests as appropriate). Multiple linear regression was used to 
model the association between carotid-radial PWV and percent emphysema after 
adjusting for potential confounders. Analyses were performed with SPSS version 14 
(Illinois, USA) and graphs were drawn using R version 2.9.2 (R Foundation, Vienna, 
Austria). 
5.3. Results 
Carotid-radial PWV was performed in 177 COPD patients, with satisfactory 
measurements obtained in 157 patients. The full cohort (n=157) and CT sub-group 
(n=73) were similar for all clinical, laboratory, haemodynamic and spirometric 
characteristics (Table 5-1). 
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Table 5-1 Characteristics in patients with and without CT measures 
 All subjects Non-CT CT subjects 
n 157 84 73 
Age 67.9 (7.6) 67.9 (8.0) 67.9 (7.2) 
Male 92 (59%) 46 (55%) 46 (63%) 
Height(cm) 166.5 (10.0) 165.4 (9.5) 167.9 (10.4) 
Weight(kg) 71.3 (18.1) 68.32 (17.4) 74.6 (18.4) 
BMI (kg/m2) 25.6 (5.6) 24.9 (5.5) 26.4 (5.8) 
Oxygen saturations* 96 (94-97) 96 (95-98) 96 (94-97) 
SGRQ total score* 50 (33-63) 50 (35-67) 4 9 (32-61) 
Pack years smoking* 40 (30-56) 43 (25-50) 40 (30-52) 
Current smoker 62 (39%) 38 (45%) 24 (33%) 
Chronic bronchitis 74 (50%) 37 (44.6%) 37 (58%) 
Ankle oedema 37 (24%) 21 (25%) 16 (22%) 
Inhaled Corticosteroid  103 (66%) 54 (64%) 49 (67%) 
Long Acting Beta 
Agonist 
83 (53%) 47 (56%) 36 (49%) 
History of ischaemic 
heart disease 
32 (20%) 19 (23%) 13 (18%) 
History of  
hypercholesterolaemia 
21 (13%) 11(13%) 10 (14%) 
History of diabetes 3 (2%) 1(1%) 2 (3%) 
Spirometry    
 FEV1 (L) 1.29 (0.58) 1.21 (0.56) 1.37 (0.59) 
 FEV1/FVC 49 (14) 49 (15) 50 (13) 
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 All subjects Non-CT CT subjects 
n 157 84 73 
 FEV1 percent 
predicted 
51 (20) 50 (20) 53 (20) 
Haemodynamic    
Heart Rate 69 (11) 69 (10) 69 (11) 
Systolic Pressure 
(mmHg) 
144 (23) 144 (24) 144 (21) 
Diastolic Pressure 
(mmHg) 
81 (11) 80 (11) 81 (12) 
Pulse Pressure 64(19) 64 (20) 63 (17) 
Mean arterial pressure 102(13) 101 (12) 102 (13) 
Carotid-radial Pulse 
Wave Velocity (m/s) 
8.69 (1.51) 8.55 (1.52) 8.85 (1.50) 
Laboratory    
Glucose (mmol/l) 6.12 (1.28) 6.03 (1.23) 6.13 (1.33) 
Cholesterol:HDL ratio 3.74 (1.09) 3.71 (1.14) 3.77 (1.04) 
White cell count 7.48 (2.10) 7.43 (2.28) 7.55 (1.87) 
Neutrophil count 4.79 (1.67) 4.91 (1.88) 4.65 (1.40) 
Platelet count 262 (66) 260 (67) 263 (65) 
CRP (mg/L)* 3.66 (1.87-7.25) 3.76 (1.98 – 8.32) 3.48 (1.67-6.72) 
Values represent Mean (SD), except * median (IQR), and % count (percentage). 
In the full cohort carotid-radial PWV was higher in men, and there were statistically 
significant associations between carotid-radial PWV and height, oxygen saturations, 
FEV1 percent predicted, FEV1/FVC ratio, heart rate, and blood pressure. There was 
no association between CRP and PWV, or between smoking pack years and carotid-
radial PWV (Table 5-2, Table 5-3 and Figure 5-1).
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Figure 5-1 Association of carotid-radial pulse wave velocity with  
emphysema severity, the FEV1/FVC ratio and FEV1 percent predicted
  101 
 
In the sub-group of patients who underwent CT, height, body mass index (BMI), 
heart rate, diastolic pressure, FEV1 percent predicted, and FEV1/FVC, were 
associated with pulse wave velocity on univariate analysis (Table 5-2). Carotid-radial 
PWV was higher in COPD patients with severe and very severe COPD (GOLD stage 
3 and 4) than in those with mild and moderate disease (GOLD stage 1 and 2, 9.05m/s 
versus 8.37 m/s p=0.004), and was greater in men than women (0.99 m/s p=0.006), 
but there was no difference in carotid-radial PWV between subjects with or without a 
history of ischaemic heart disease or between current and ex-smokers (Table 5-3). 
Pack years smoking history was not associated with PWV (r=-0.18, p= 0.13), nor 
with emphysema severity (r=- 0.96, p=0.43). No relationship was found between 
hsCRP and PWV, nor between leukocytes and carotid-radial PWV (Table 5-2).  
Table 5-2 Associations between continuous variables and carotid-radial 
PWV in the full cohort and CT subgroup (Pearson’s correlations) 
 All Subjects  n=157  CT Subjects n=73 
  r value p value  r value p value 
Age -0.013 0.868  -0.137 0.246 
Clinical      
Height(cm) 0.266 0.001  0.279 0.017 
Weight (kg) -0.020 0.806  -0.332 0.332 
BMI (kg/m2) -0.155 0.052  -0.280 0.016 
Oxygen saturations -0.167 0.039  -0.114 0.336 
SGRQ total score 0.073 0.366  -0.072 0.547 
Pack years smoking -0.023 0.780  - 0.180 0.132 
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 All Subjects  n=157  CT Subjects n=73 
  r value p value  r value p value 
 FEV1 (l) -0.012 0.881  0.029 0.805 
 FEV1/FVC -0.295 <0.001  -0.419 0.001 
 FEV1 percent predicted -0.208 0.009  -0.243 0.038 
Glucose (mmol/l) 0.138 0.085  -0.024 0.843 
Cholesterol:hdl ratio -0.048 0.562  -0.082 0.496 
Log CRP -0.63 0.435  -0.199 0.093 
White cell count 0.023 0.772  0.023 0.846 
Neutrophil count 0.039 0.634  -0.026 0.828 
Platelet count -0.042 0.615  <0.001 >0.999 
















Pulse Pressure (mmHg) -0.027 0.740  -0.095 0.423 
Percent emphysema      
- 950 Hounsfeld units n/a n/a  0.471 <0.001 
- 910 Hounsfeld units n/a n/a  0.476 <0.001 
15th Percentile density 
(Hu) 
n/a n/a  
- 0.409 <0.001 
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Table 5-3 Mean Difference in carotid-radial PWV between dichotomous 
groups in the full cohort and CT subgroup (t-tests) 
 Full Cohort n=157  CT Subgroup n=73 
 m/s p value  m/s p value 
Gender 0.783 0.001  0.99 0.006 
Current Smoking 0.181 0.464  0.30 0.418 
Chronic Bronchitis 0.338 0.173  0.25 0.509 
Ankle Oedema 0.369 0.195  0.05 0.906 
Inhaled Corticosteroid 0.023 0.929  0.42 0.322 
Long Acting Beta 
Agonist 
0.156 0.521  0.47 0.182 
Ischaemic Heart Disease 0.351 0.242  0.34 0.480 
Hypercholesterolaemia 0.591 0.095  0.80 0.124 
In  adjusted  analyses,  severity  of  emphysema  (r2=0.13, p=0.002) and mean arterial 
pressure (r2 =0.08, p=0.043) were the factors most closely associated with PWV, 
with BMI and gender almost reaching statistical significance (Table 5-4). 
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Table 5-4 PWV regressed on gender, height, body mass index, heart 




error Partial r2  p value 
Male gender 0.381 0.414 0.01 0.36 
Height (m) 0.017 0.018 0.01 0.36 
Body Mass Index (kg/m2) -0.049 0.028 0.05 0.09 
Heart Rate 0.016 0.016 0.06 0.05 
Mean Arterial Pressure 
(mmHg) 0.026 0.013 0.06 0.04 
Log CRP -0.431 0.34 0.02 0.21 
FEV1 percent Predicted 0.652 0.95 0.01 0.50 
Percent emphysema 4.358 1.525 0.11 0.006 
CT subjects n= 71, global significance test (ANOVA) p<0.001, r2 =0.409 
In sensitivity analyses, carotid-radial PWV was associated with severity of 
emphysema regardless of whether percent emphysema was calculated using the -910 
Hu, -950Hu cut-offs or whether the 15th percentile was used, and after additionally 
adjusting for age, smoking status and pack years smoking. 
5.4. Discussion 
Emphysema severity was associated with arterial stiffness, as measured by carotid-
radial pulse wave velocity independent of cigarette smoking in patients with COPD. 
The association was also independent of age, sex, blood pressure, hsCRP, 
dyslipidaemia, inflammation, hypoxaemia, and airflow limitation. 
Carotid-femoral pulse wave velocity, a distinct measure of arterial stiffness, predicts 
mortality in a wide range of settings, and has previously been found to be higher in 
COPD patients than in controls (Sabit et al. 2007; Maclay, McAllister, Mills, 
Paterson, et al. 2009). The finding from this study, that arterial stiffness as measured 
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by carotid-radial pulse wave velocity is associated emphysema severity independent 
of FEV1 percent predicted, suggests that COPD patients with an emphysematous 
phenotype may be at increased cardiovascular risk compared to patients with a non-
emphysematous phenotype, and longitudinal studies are now required. 
Cigarette smoke exposure has a causal relationship with both COPD and 
cardiovascular disease. It was therefore important to address smoking as a potential 
confounder, and this was done by adjusting for smoking status and pack-years. Pack 
years is the most widely used measure for assessing lifetime cigarette smoke 
exposure, but is based upon self-recall over several years and as such inaccurate 
reporting  is  likely.  It  is  unlikely  that  error  in  reported  smoking  was  differential  by  
pulse wave velocity, but non-differential error in the measurement of cigarette smoke 
exposure may explain why no association was found between pack-years and 
emphysema and between pack-years and PWV in this study, as well as between 
pack-years and these measures in previous studies (Sabit et al. 2007; Makita et al., 
the Hokkaido COPD Cohort Study Group 2007). Consequently, residual 
confounding by cigarette smoke exposure needs to be considered as a potential 
explanation for the observed association between carotid-radial PWV and percent 
emphysema. 
However, the association between carotid-radial PWV and percent emphysema was 
independent of FEV1 which is also likely to be a marker of cigarette exposure. In 
addition, the patients studied had substantial smoking histories and were susceptible 
to cigarette smoke as evidenced by clinical COPD. Consequently variability in 
smoke exposure within this group might not be as important as in unselected 
samples. Moreover, the association between emphysema and PWV was strong, and 
would  be  unlikely  to  be  entirely  abolished  even  if  a  more  accurate  measure  of  
cigarette smoke exposure were available.  
In a previous case-control study of carotid-femoral PWV in COPD, there was an 
association between Il-6 and carotid-femoral PWV  and the authors postulated that 
the increased systemic inflammation seen in COPD may be responsible for the 
observed increase in arterial stiffness (Sabit et al. 2007). In this larger cohort there 
was no association between carotid-radial PWV and hsCRP, whose release is 
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stimulated by Il-6. Nor was there an association between emphysema severity and 
hsCRP. As such, the results of this study do not support the hypothesis that systemic 
inflammation is an important cause of arterial stiffness in patients with COPD. 
Nonetheless,  a different measure of PWV was used than by Sabit  et  al  (Sabit  et  al.  
2007), and there may be other circulating inflammatory factors, oxidised lipids or 
proteins which, through their effect on endothelium and smooth muscle, link the lung 
inflammation and oxidative stress, which are found in patients with emphysema, to 
the development of arterial stiffness. 
Another possible mechanism to explain the association between emphysema severity 
and arterial stiffness is hypoxia. There was no association between pulse oximetry 
oxygen saturations and arterial stiffness after controlling for other variables. 
Although pulse oximetry does not directly measure tissue hypoxia, it seems unlikely, 
given the relatively large regression co-efficient found, that tissue hypoxia could 
completely account for the observed association between emphysema and carotid-
radial PWV, even with a measure such as mixed venous oxygenation. 
There are a number of pathological features common to arterial stiffness and 
emphysema which suggest that, in some individuals with COPD, there may be an 
acquired or inherited tendency to develop emphysema and arterial stiffness, as was 
discussed in Section 1.4.5. 
5.4.1. Limitations 
In previous studies increased BMI was associated with increased arterial stiffness 
(Mitchell  et  al.  2005),  presumably  as  a  result  of  the  effects  of  obesity  and  the  
metabolic syndrome. Instead, in the current study, low BMI was associated with 
increased PWV on univariate testing, and was of borderline significance on 
multivariable testing (Table 5-4). However, low BMI is a marker of more severe 
COPD (Celli et al. 2004) and is likely to reflect a more catabolic state, which may 
explain this apparently contradictory finding, as well as explaining why other 
metabolic factors such as hyperglycaemia and hypercholesterolaemia were not 
significantly associated with PWV in these patients. 
CT scanning was not performed in all patients, and those who had CT scanning were 
not selected randomly. However, patients with CT measures were very similar to 
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those  without,  and  in  particular  were  very  similar  in  terms  of  PWV  and  FEV1. As 
such, selection bias is unlikely to account for the observed association. 
PWV was measured via the carotid-radial method, which is associated with coronary 
artery plaque burden, and increases linearly with age (Hall et al., with McEniery et 
al., Yasmin 2005; McLeod et al. 2004). Using this technique meant PWV could be 
performed with subjects lying supine at 15 degrees which meant that patients with 
severe dyspnoea could be included in the study. However, carotid-femoral PWV (in 
which the tonometer is placed over the femoral artery) rather than carotid-radial 
PWV is the recognised “Gold standard” measure of arterial stiffness (Laurent et al., 
on behalf of the European Network for Non-invasive Investigation of Large Arteries 
2006). No measure of arterial stiffness has been validated as a marker of 
cardiovascular risk in a COPD population, but carotid-femoral PWV predicts 
cardiovascular risk in longitudinal studies in a variety of conditions (Laurent et al., 
on behalf of the European Network for Non-invasive Investigation of Large Arteries 
2006). As such, had the same association between PWV and emphysema been shown 
using this measure rather than carotid-radial, there would have been a stronger case 
for longitudinal studies to examine emphysema severity as a predictor of 
cardiovascular mortality. 
Carotid-radial PWV measures the travel of the wave-form from the ascending aorta 
to the radial artery, while carotid-femoral PWV measures travel of the wave-form 
from the ascending aorta to the iliac artery. There is considerable heterogeneity 
across the vascular tree, the aorta differs considerably along its length, the relative 
amount of elastin decreases, and collagen and smooth muscle increase as the vessel 
travels distally (Nichols & O’Rourke 1990; Duprez et al. 2007). Therefore, to further 
explore whether elastin degradation is fundamental to the association between 
emphysema, FEV1 and aortic stiffness a local measure of arterial stiffness in the 
proximal aorta may provide additional information. This is addressed in Chapter 6. 
5.4.2. Conclusion 
Severity of emphysema correlates with carotid-radial PWV a measure of arterial 
stiffness in patients with COPD. This association may be due to systemic effects of 
COPD (inflammation, oxidative stress and hypoxia), to environmental factors such 
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as pollution, or to a shared susceptibility to degradation of elastin and other 
components of the extra-cellular matrix in both systemic arteries and the lung. 
Subsequent chapters explore whether different regions of the arterial tree have 
different relationships with lung function and emphysema severity. 
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6. Cross sectional study in multi-centre general 
population sample: proximal aortic distensibility 
6.1. Introduction 
Arterial stiffness, as measured by carotid-femoral PWV, predicts cardiovascular 
mortality independent of age, sex, smoking history, cholesterol, and mean arterial 
blood pressure, and is associated with coronary atheroma burden and known 
cardiovascular risk factors such as smoking (Boutouyrie et al. 2002; Mattace-Raso et 
al. 2006; Willum Hansen et al. 2006). Carotid-femoral PWV was found to be higher 
in COPD patients than in controls matched on age and sex (Sabit et al. 2007), and to 
be associated with FEV1 in healthy men (Bolton et al. 2009; Zureik, Benetos, et al. 
2001). 
Emphysematous lung and stiffened arteries share a number of pathophysiological 
features, including elastin degradation, abnormal collagen remodelling (Finlay et al. 
1996; Zieman et al. 2005), and enhanced proteolytic activity (Wallace et al., with 
Yasmin 2005; Finlay et al. 1997). Loss of skin elasticity is also associated with 
emphysema severity independent of age and smoking history (Patel et al. 2006). 
Therefore there may be a shared susceptibility to connective tissue degradation in 
both the artery and lung leading to arterial stiffening and emphysema respectively. 
Associations between emphysema severity on CT and vascular measures have been 
reported. Impaired flow mediated dilation (a marker of endothelial vasomotor 
function)  is  associated  with  emphysema  severity  on  CT  (Barr,  Mesia-Vela,  et  al.  
2007), and in Chapter 5, an association was reported between emphysema severity 
and carotid-radial pulse wave velocity. 
There is considerable heterogeneity across the vascular tree, the aorta differs 
considerably along its length, the relative amount of elastin decreases, and collagen 
and smooth muscle increase as the vessel travels distally (Nichols & O’Rourke 1990; 
Duprez  et  al.  2007).   It  is  not  known  whether  emphysema  severity  or  FEV1 is 
associated with increased stiffness in central elastic arteries. 
Therefore, the aim of this chapter is to test the hypothesis that arterial stiffness in the 
proximal aorta, measured via reduced distensibility of the ascending aorta on 
magnetic resonance (MR), a well-validated measure of local central arterial stiffness 
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(Oliver & Webb 2003; Malayeri et al. 2008; Laurent et al., on behalf of the European 
Network for Non-invasive Investigation of Large Arteries 2006), is associated with 
severity of emphysema and reduced FEV1 in a large population-based cohort, 
including participants with airflow limitation. 
6.2. Methods 
6.2.1. Population studied 
The Multi-Ethnic Study of Atherosclerosis (MESA) is a multi-centre prospective 
cohort study designed to investigate sub-clinical cardiovascular disease in individuals 
without clinical cardiovascular disease (Bild et al. 2002).  In 2000 to 2002, MESA 
recruited 6,814 men and women aged 45 to 84 from six U.S. communities: Forsyth 
County, NC; Northern Manhattan and the Bronx, NY; Baltimore City and Baltimore 
County, MD; St. Paul, MN; Chicago, IL; and Los Angeles, CA.  MESA participants 
were European-American white, African-American, Hispanic, or Asian-American 
(mostly of Chinese origin).  Exclusion criteria were clinical cardiovascular disease 
(physician  diagnosis  of  heart  attack,  stroke,  transient  ischemic  attack,  heart  failure,  
angina, current atrial fibrillation, and any cardiovascular procedure), weight >300 
lbs,  pregnancy  or  impediment  to  long-term  participation  (Bild  et  al.  2002).  MESA  
protocols and all studies described herein have been approved by the Institutional 
Review Boards of all collaborating institutions, and this analysis was approved by 
Lothian Research Ethics Committee. 
The MESA-Lung Study enrolled 3,965 MESA participants, of 4,483 sampled 
randomly from among those who consented to genetic analyses, underwent baseline 
measures of endothelial function, and attended an examination during the MESA-
Lung recruitment period in 2004-2006 (99%, 89%, and 91% of the MESA cohort, 
respectively).  Chinese-Americans were over sampled to improve the precision of 
estimates for this group. For the current analysis related to obstructive lung disease, 
322 (9%) participants with restrictive spirometry were excluded. Restrictive 
spirometry was defined as a FVC less than the lower limit of normal (LLN) with a 
forced expiratory volume in one second FEV1/FVC ratio above 0.70 (Hankinson et  
al. 1999). 
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6.2.2. Aortic distensibility 
Consenting participants underwent a cardiac MR scan in 2000-2002. The protocol, 
its  reliability  and  characteristics  of  MESA  participants  with  and  without  MR  
measures have been previously described (Malayeri et al. 2008; Cheung et al. 2004). 
All imaging was performed on 1.5 T magnets with a 4-element phased-array surface 
coil positioned anteriorly and posteriorly, electrocardiographic gating, and brachial 
artery blood pressure monitoring. 
Aortic cross sectional area at the level of the right pulmonary artery during systole 
and diastole were calculated using an automated contour routine using the software 
FLOW (Medis, Netherlands). Brachial blood pressure was measured with the 
participant supine in the MR scanner before and after the scan. Proximal aortic 
distensibility was calculated as 1000 x (maximum area – minimum area) / (minimum 
area x brachial pulse pressure). Left ventricular stroke volume was calculated as 
previously described (Heckbert et al. 2006). 
6.2.3. Spirometry 
Spirometry was conducted in 2004-2006 in accordance with the ATS/ERS guidelines 
(Miller et al. 2005). All participants performed at least three acceptable manoeuvres.  
Tests were conducted using a dry-rolling-sealed spirometer and software that 
performed automated quality checks as manoeuvres were performed (Occupational 
Marketing, Inc., Houston, TX).   All spirometry exams were reviewed by one 
investigator and each test was graded for quality, as previously described (Hankinson 
et al. 2009). Participants with no acceptable curves were excluded from spirometry 
analyses. Airflow limitation was defined as pre-bronchodilator FEV1/FVC 0.7 and 
FEV1 <80% of predicted.  The ICC of both the FEV1 and the FVC on random 10% 
repeat testing was 0.99. 
6.2.4. CT emphysema measurement 
Quantitative measures of emphysema on CT scan were performed on the lung fields 
of MESA cardiac CT scans, which imaged approximately 70% of the lung volume 
from the carina to the lung bases.  Cardiac CT scans were performed at full 
inspiration on multi-detector (MD) and electron-beam CT scanners in 2000-02 
following a standardized protocol (Carr et al. 2005). Two scans were performed on 
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each participant; the scan with the higher air volume was used for analyses except in 
cases of discordant scan quality, in which case the scan with higher quality scan was 
used (Hoffman et al. 2009). 
 Image attenuation was assessed using modified Pulmonary Analysis Software Suite 
at a single reading centre by trained readers without knowledge of other participant 
information.  Attenuation of air was also measured outside the chest and in the right 
and left main bronchi.   Percent emphysema was defined as the percentage of the 
total voxels in the lung which fell below -910 Hu.  The ICC on blinded re-reads was 
0.94. Percent emphysema measures from the carina to lung base are highly correlated 
(r=0.99) with full-lung measures on the same full-lung scans in smokers. 
Emphysema measures from MESA cardiac scans correlated with full-lung scans 
(e.g., r=0.93 on MDCT scanners) (Hoffman et al. 2009). 
6.2.5. Potential confounders 
Age, gender, race/ethnicity, educational attainment, and medical history were self-
reported.  Current smoking was defined as self-report of a cigarette in the last 30 
days or urinary cotinine level at the time of CT exam greater than 100 ng/ml 
(Immulite 2000 Nicotine Metabolite Assay; Diagnostic Products Corp., Los Angeles, 
CA). 
Asthma was defined as self-report of physician-diagnosed asthma before age 45 
years in order to avoid over-correction for COPD misdiagnosed as asthma above that 
age, which is common and differential by gender (Chapman et al. 2001). 
Height, weight and resting blood pressure were measured using standard techniques, 
the latter with the Dinamap Monitor PRO 100 (Critikon, Tampa, FL) automated 
oscillometric device (Ni et al. 2006). Hypertension was defined as a systolic blood 
pressure >140 mm Hg, a diastolic blood pressure >90 mmHg, or currently taking 
medications for BP control (Chobanian et al., the National High Blood Pressure 
Education Program Coordinating Committee 2003).  
Glucose and lipids were measured after a 12-h fast. The presence of diabetes mellitus 
was based on self-reported physician diagnosis, use of insulin and/or oral 
hypoglycemic agent, or a fasting glucose value >126 mg/dL.  Serum glucose after 
12-hour fast was measured by rate reflectance spectrophotometry on the Vitros 
  113 
analyzer (Johnson & Johnson Clinical Diagnostics, Inc., Rochester, NY).  Total 
cholesterol was measured using a cholesterol oxidase method (Roche Diagnostics), 
as was HDL after precipitation of non-HDL cholesterol with magnesium/dextran, 
triglycerides using Triglyceride GB reagent (Roche Diagnostics). LDL cholesterol 
was calculated in plasma specimens having a triglyceride value <400 mg/dl using the 
formula of Friedewald et al (Friedewald et al. 1972).  
6.2.6. Statistical analysis 
Demographics and medical characteristics were tabulated by respiratory condition. 
Among individuals without self-reported asthma before age 45, participants with 
normal lung function and with various degrees of severity of severity of airflow 
limitation were compared. Multiple linear regression of proximal aortic distensibility 
on lung density and lung function was performed. Analyses adjusted for study site, 
age, race/ethnicity, gender, height, body mass index, cigarette smoking status, pack 
years, diabetes, hypertension, educational attainment, serum low density lipoprotein, 
high density lipoprotein, and glucose concentration, antihypertensive therapy, and 
lipid lowering therapy. 
Sensitivity analyses were performed using percent emphysema measures corrected 
for both outside and inside air. Interactions were tested with multiplicative terms in 
regression models. Generalised additive models with loess smoothing functions for 
continuous variables were used to test for non-linearity and to allow for the flexible 
specification of relationships. Smoothing functions did not improve model fit of lung 
function and lung density, however, and terms were treated as linear.  Analyses were 
performed with SPSS version 14 (Illinois, USA) and R 2.6.2 (R Foundation, Vienna, 
Austria). All p-values were two-tailed with p <0.05 considered statistically 
significant. 
6.3. Results 
Of the participants in the MESA Lung Study with valid spirometry measures and 
without restrictive lung disease, 1,917 had proximal aortic distensibility MR 
measures (Figure 6-1).  
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Figure 6-1 Flow-chart of inclusion/exclusion in study 
Those with proximal aortic distensibility MR measures were younger and less likely 
to have hypertension and diabetes but were otherwise similar to those without such 
measures (Table 6-1). 
Participants with proximal aortic distensibility MR measures were on average 60 
years old and 47.1% were male. Thirty-eight percent were Caucasian, 15.9% were 
Chinese, 28.6% African American, and 17.8% were Hispanic.  Median proximal 
aortic distensibility was 0.19 (interquartile range 0.11 to 0.24) mmHg-1.  Ten percent 
of participants had airflow limitation (Table 6-1).  Those with airflow limitation were 
older, more likely to be male and to have hypertension, diabetes, chronic bronchitis 
and a history of smoking (Table 6-2). 
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Table 6-1 Characteristics of participants with and without proximal 
aortic distensibility measures 






N 1613 1917 
Age, mean (SD), years 63 (10) 60 (10) 
Gender – male, n (%) 832 (51.6) 903 (47.1) 
Height, mean (SD), cm 166 (10) 167 (10) 
BMI, mean (SD), kg/m2 28 (6) 27 (5) 
Ethnicity, n (%)  
    Caucasian 
    Chinese 
    African-American 











Smoking status, n (%)  
    Never Smoked 
    Ex-smoker 









Pack Years, median (IQR)  19 (7-35) 17 (7-35) 
Spirometry, mean (SD), % 
    FEV1 percent predicted 
    FVC percent predicted 









MRC Bronchitis, n (%) 120 (7.5) 154 (8.1) 
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CT percent emphysema, median 
(IQR), % 14.3 (7.3-23.6) 15.3 (7.9-25.6) 
Asthma (self reported, aged <45) 115 (7.1) 164 (8.6) 
Self reported, n (%) 
    Hypertension  
    Diabetes 
   Antihypertensive medication 











BP, mean (SD), mmHg 
     Systolic Blood Pressure 
     Diastolic Blood Pressure 









Heart Rate, mean (SD), beats/min 63 (9) 63 (9) 
Lipids, mean (SD), mg/dl 
    LDL Cholesterol 
    HDL Cholesterol 









CRP, median (IQR), mg/L 1.83 (0.83-4.05) 1.64 (0.71-3.76) 
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<0.7 and FEV1 
percent 
predicted      
50% to 80% 
FEV1/FVC 
<0.7 and FEV1 
percent 
predicted          
 50% 
N 1375 164 230 128 20 
Age, mean (SD), years 59 (9) 58 (10) 66 (10) 63 (9) 65 (7) 
Gender – male, n (%) 606 (44.1) 67 (40.9) 149 (64.8) 68 (53.1) 13 (65) 
Height, mean (SD), cm 166 (10) 167 (10) 170 (10) 169 (10) 168 (10) 
BMI, mean (SD), kg/m2 28 (5) 28 (5) 26 (4) 26 (4) 29 (6) 
Caucasian 461 (33.5) 70 (42.7) 118 (51.3) 66 (51.6) 7 (35) 
Chinese 248 (18.0) 15 (9.1) 29 (12.6) 9 (7.0) 3 (16) 
African-American 397 (28.9) 50 (30.5) 59 (25.7) 38 (29.7) 5 (25) 
Hispanic 269 (19.6) 29 (17.7) 24 (10.4) 15 (11.7) 5 (25) 
Never Smoked 733 (53.3) 87 (53.0) 90 (39.1) 33 (25.8) 1 (5) 
Ex-smoker 488 (33.5) 55 (33.5) 106 (46.1) 60 (46.9) 9 (45) 
Current Smoker 154 (11.2) 22 (13.4) 34 (14.8) 35 (27.3) 10 (50) 
Pack Years, median (IQR) 15 (6-32) 15 (6-28) 24 (11-47) 29 (14-47) 52 (27-68) 
FEV1 percent predicted, mean (SD), % 100 (14) 85 (18) 96 (11) 70 (9) 40 (9) 
FVC percent predicted, mean (SD), % 98 (13) 94 (16) 109 (13) 86 (12) 67 (16) 
FEV1/FVC ratio, , mean (SD), % 79 (5) 70 (10) 66 (4) 62 (7) 47 (13) 
MRC Chronic Bronchitis, n (%) 92 (6.7) 26 (15.9) 18 (7.8) 12 (9.5) 6 (30.0) 
CT Percentage Emphysema, median (IQR),% 14 (7-22) 17 (10-27) 25 (15-36) 18 (10-32) 27 (10-33) 
















<0.7 and FEV1 
percent 
predicted      
50% to 80% 
FEV1/FVC 
<0.7 and FEV1 
percent 
predicted          
 50% 
Hypertension 519 (37.7) 62 (37.8) 90 (39.1) 58 (45.3) 9 (45) 
Diabetes 119 (8.7) 10 (6.1) 13 (5.7) 12 (9.4) 5 (25) 
Antihypertensive medication 437 (31.8) 54 (32.9) 77 (33.5) 50 (39.1) 9 (45) 
Lipid Lowering Therapy 197 (14.3) 21 (12.8) 39 (17.0) 17 (13.3) 4 (20) 
Systolic BP, mean (SD), mmHg 123 (19) 123 (19) 123 (19) 122 (20) 128 (16) 
Diastolic BP, mean (SD), mmHg 72 (10) 72 (9) 71 (10) 70 (11) 72 (8) 
Pulse pressure. mean (SD), mmHg 51 (15) 51 (16) 52 (15) 52 (15) 56 (13) 
Heart rate, mean (SD), bpm 63 (9) 63 (8) 60 (9) 62 (10) 69 (14) 
LDL Cholesterol, mean (SD), mg/dl 119 (29) 116 (33) 114 (30) 115 (32) 116 (29) 
HDL Cholesterol, mean (SD), mg/dl 52 (15) 53 (15) 51 (15) 51 (15) 46 (9) 
Triglycerides, mean (SD), mg/dl 129 (93) 128 (81) 109 (56) 124 (97) 136 (61) 
CRP, median (IQR), mg/L 1.61 1.79 1.5 2.09 5.18 
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6.3.1. Lung function and proximal aortic distensibility 
Proximal aortic distensibility was not associated with FEV1 after adjusting for study 
centre, age, sex, race/ethnicity, height, and BMI (-0.02 mmHg-1; 95% CI -0.15 to 
0.11 mmHg-1, p =0.75) or after additionally adjusting for cigarette smoking status, 
pack years, diabetes, hypertension, educational attainment, serum low density 
lipoprotein, high density lipoprotein, and glucose concentration, antihypertensive 
therapy, and lipid lowering therapy (-0.04 mmHg-1; 95% CI -0.16 to 0.09, p=0.60). 
Results for FVC, and the FEV1/FVC ratio were similarly null (Table 6-3). 
6.3.2. Airflow limitation and proximal aortic distensibility 
Similarly, reduced proximal aortic distensibility was not evident in participants with 
moderate or severe airflow limitation, indeed compared to participants with normal 
lung function, proximal aortic distensibility was higher for those with moderate 
airflow limitation (0.24 mmHg-1; 95% CI 0.02 to 0.46 mmHg-1) and severe airflow 
limitation (0.09 mmHg-1; 95% CI -0.44 to 0.62 mmHg-1). 
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Table 6-3 Associations of proximal aortic distensibility, lung function 
and percent emphysema 
Exposure 
Increase in Aortic Distensibility 
(mmHg-1) per one unit increase in 
Exposure (95% CI) 
p value 
 FEV1 (litres) 
  Model 1 
  Model 2 
 
-0.02 (-0.15 to 0.11) 





  Model 1 
  Model 2 
 
0.02 (-0.09 to 0.13) 




 FEV1/FVC (ratio) 
  Model 1 
  Model 2 
 
-0.35(-1.00 to 0.30) 




Model 1: adjusted for study site, age, race, gender, height, and body mass index. 
Model 2: adjusted for model 1 and heart rate, cigarette smoking status, pack years, 
diabetes, hypertension, educational attainment, serum low density lipoprotein, high 
density lipoprotein, and glucose concentration, antihypertensive therapy, lipid 
lowering therapy and left ventricular stroke volume. 
6.3.3. Percent emphysema and proximal aortic distensibility 
Proximal aortic distensibility was not associated with percent emphysema after 
adjusting for study site, age, race/ethnicity, gender, height, and body mass index, nor 
after additionally adjusting for study site, age, race/ethnicity, gender, height, body 
mass index, cigarette smoking status, pack years, diabetes, hypertension, educational 
attainment, serum low density lipoprotein, high density lipoprotein, and glucose 
concentration, antihypertensive therapy, lipid lowering therapy and scanner type and 
protocol (0.03 mmHg-1; 95% CI -0.02 to 0.09 mmHg-1, p=0.19). 
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6.3.4. Sensitivity Analyses 
Sensitivity analyses limited to participants who had smoked greater than 10, 20 and 
50 pack-years produced similar results. Exclusion of participants with asthma 
diagnosed before the age of 45 did not affect the results; neither did exclusion of 
participants with any diagnosis of asthma, nor use of CT percent emphysema 
measures corrected for outside air or airways air, or use of the 15th percentile point. 
Additional adjustment for self-reported use of bronchodilators, steroids, or 
methylxanthines had little impact on the results. There was no evidence for effect 
modification on an additive scale by gender, race/ethnicity, smoking status, study 
site, CT scanner type or severity of airflow limitation on spirometry. Nor was there 
any evidence of departure from linearity when explored using generalised additive 
models of proximal aortic distensibility on FEV1 (Figure 6-2).
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Figure 6-2 Association of proximal aortic distensibility FEV1 (ml) 
Obtained using generalised additive model of proximal aortic distensibility on FEV1 adjusting for study site, age, race, gender, height, body 
mass index, heart rate, cigarette smoking status, pack years, diabetes, hypertension, educational attainment, serum low density lipoprotein, 
high density lipoprotein, and glucose concentration, antihypertensive therapy, lipid lowering therapy, left ventricular stroke volume and CT 
scanner type.  Solid line=smoothed regression line, dashed lines=95% confidence intervals; vertical lines=rug plot of data points. There 
was no evidence of a linear association between proximal aortic distensibility and FEV1 (p=0.43).
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Since proximal aortic distensibility is comprised of a ratio, and the use of ratios as 
dependent variables in regression models can produce false correlations (Kronmal 
1993), proximal aortic distensibility was also modelled using the change in area of 
the aorta as the dependent variable adjusting for minimum area of the aorta and 
brachial pulse pressure as independent variables. The findings were qualitatively 
similar. 
Since cardiac MR measures of aortic distensibility estimate the central distending 
pressure from the brachial artery pressure, maximal cross sectional area was also 
modelled as the outcome measure. The findings were qualitatively similar. 
6.4. Discussion 
There was no evidence for an association between distensibility in the proximal 
ascending aorta and FEV1 or  percent  emphysema in  this  large  sample  with  precise  
measures. Nor was distensibility lower in those participants with airflow limitation 
compared to the remaining participants. 
Previous population-based studies that have examined associations between lung 
function or airflow limitation and PWV are limited to two European studies of 194 
and 827 middle aged men (Zureik, Benetos, et al. 2001; Bolton et al. 2009), in which 
associations were found, and one negative study in 678 healthy Japanese-Americans 
(Taneda et al. 2004). PWV has previously been found to be higher in patients with 
COPD than  controls  matched  on  age,  sex  and  smoking  (Sabit  et  al.  2007;  Maclay,  
McAllister, Mills, Paterson, et al. 2009). All these studies employed carotid-femoral 
PWV which measures pulse wave transition from the aorta to the iliac artery. In 
Chapter 5 an association between emphysema and carotid-radial PWV was reported. 
The discrepant findings as regards the associations between lung function and arterial 
stiffness may result from differences in the populations studied, the study design, the 
site at which arterial stiffness was measured, and the measures of arterial stiffness 
employed. 
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6.4.1. Differences in anatomical site of arterial stiffness 
Proximal  aortic  distensibility  measured  via  cardiac  MR  was  not  associated  with  
reduced lung function, airflow limitation or percent emphysema in the MESA cohort. 
Cardiac MR distensibility and PWV are both well-validated measures of aortic 
stiffness (Oliver & Webb 2003; Laurent et al., on behalf of the European Network 
for Non-invasive Investigation of Large Arteries 2006), and are both associated with 
markers of coronary artery plaque burden (Giannattasio et al. 2007; van Popele et al. 
2006), endothelial dysfunction (Gullu et al. 2006; Newby et al., with McEniery et al., 
Yasmin 2006), and peripheral microvascular dysfunction (Cheung et al. 2007; 
Mitchell et al. 2005), although only carotid-femoral PWV has been validated in 
longitudinal studies as a predictor of cardiovascular risk (Laurent et al., on behalf of 
the European Network for Non-invasive Investigation of Large Arteries 2006).  
However, each measures stiffness at a different site. Carotid-femoral PWV measures 
stiffness regionally across the whole thoraco-abdominal aorta, carotid-radial across 
the aorta to the radial artery, and cardiac MR measures stiffness in one local site, in 
this case the ascending aorta. The proximal aorta contains a higher ratio of elastin to 
collagen, has less smooth muscle, and stiffens more with ageing than more distal 
aortic regions (Apter 1967; Duprez et al. 2007; Harkness et al. 1957; Rogers et al. 
2001). Therefore, anatomical and physiological differences in the arterial regions 
studied, might explain why there was no association between proximal aortic 
distensibility and FEV1 and airflow limitation in MESA unlike the majority of 
previous reports, or between proximal aortic distensibility and percent emphysema, 
unlike the association between carotid-radial PWV and percent emphysema reported 
in Chapter 5.   
In 162 participants selected from the Anglo-Cardiff Collaborative Trial the strongest 
associations between age and aortic stiffness measured via MR were found in the 
abdominal aorta and the weakest in the aortic arch, while the converse was true for 
aortic diameter in systole. The authors postulated that the latter phenomenon might 
be a compensatory mechanism in the presence of increased distal aortic stiffness 
(Hickson et al. 2010). Therefore, we might have expected to see increased aortic 
diameter in patients with lower FEV1, even if the primary mechanism for increased 
stiffness occurs distally. 
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6.4.2. Technical differences in measurement of arterial 
stiffness 
However, PWV and cardiac MR differ considerably in the methods used to measure 
arterial stiffness which may also explain the discrepant findings. 
Although cardiac MR allows accurate estimates of the cross-sectional area of defined 
arterial segments in systole and diastole, subsequent calculations of distensibility also 
require the distending pressure. Central pulse pressure cannot be directly measured 
using MR and instead is estimated from brachial pulse pressure. Use of this 
estimation tends to bias measures of association between ageing and distensibility 
towards the null (Duprez et al. 2007), and may have a similar effect on associations 
between aortic distensibility and FEV1 or airflow limitation. 
However, ageing-related changes such as elastin fragmentation and collagen 
remodelling also cause an increase in the diameter of the ascending aorta (Nichols & 
O'Rourke 1990), and this measure does not require any estimate of pulse pressure. 
Aortic cross sectional area was 55 mm2 greater with each decade of life, but there 
was no association between aortic cross sectional area and either percent emphysema 
or FEV1, implying that aging-like changes in the ascending aorta are not associated 
with reduced FEV1, airflow limitation or increased percent emphysema (data not 
shown). 
Moreover, in PWV measured via applanation tonometry the distance the wave-form 
travels  is  estimated  from body surface  measurements  (e.g.  sternal  notch  to  femoral  
pulse), which may make it is more prone to measurement bias than cardiac MR. 
FEV1 and  CT  measures  of  emphysema  also  relate  to  height  and  therefore  bias  in  
measurement may contribute to previously reported associations between PWV and 
lung function, for example if body surface area measurements systematically 
underestimate vessel length in taller individuals. PWV systematically overestimates 
arterial stiffness in older individuals as a consequence of the increased tortuosity in 
the abdominal aorta which is seen with ageing (Oliver & Webb 2003), and it is not 
known whether aorta tortuosity is affected by changes in emphysematous lungs, such 
as hyperinflation, although bias from body surface measurement is less likely to 
explain the association between percent emphysema and carotid-radial PWV. 
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6.4.3. Differences in populations studied 
An additional consideration is that MESA participants were identified as having 
airflow limitation on screening spirometry, whereas subjects in the two case-control 
studies and in the study detailed in Chapter 5 participants were recruited from 
amongst patients who had presented to a clinician with symptoms suggestive of 
COPD as well as airflow limitation on spirometry. Individuals who presented 
clinically  with  COPD  are  likely  to  have  had  more  co-morbidity,  to  have  regularly  
used medication which can affect endothelial and vasomotor function such as beta-
agonist and corticosteroids therapy, and to have experienced acute exacerbations of 
COPD. Therefore, the spectrum of disease among those with airflow limitation in the 
MESA cohort was milder than in the studies based upon patients recruited from 
clinical settings, which might explain the discrepant findings for emphysema severity 
and measures of arterial stiffness between the studies. 
However, disease severity is unlikely to account for the lack of association between 
FEV1 and aortic distensibility since carotid-femoral PWV has been associated with 
FEV1 in studies which obtained samples from the general population (Zureik, 
Benetos,  et  al.  2001;  Bolton  et  al.  2009).  In  MESA,  and  in  the  study  of  Japanese-
Americans reported by Taneda et al (Taneda et al. 2004), in which arterial stiffness 
was not associated with FEV1, smoke exposure was lower than in the two European 
population based studies which reported associations between PWV and FEV1. 
However, this seems an unlikely reason for the discrepancy between the studies, as 
Zureik et al found that FEV1 was associated with PWV even amongst never smokers 
(Zureik, Benetos, et al. 2001). 
In MESA, participants were very well characterised in terms of cardiovascular risk 
factors, but even in unadjusted models proximal aortic distensibility was not 
associated with FEV1 or percent emphysema, so confounding is unlikely to account 
for the divergent findings. 
6.4.4. Limitations 
A relatively large proportion of MESA participants did not have proximal aortic 
distensibility measures on MR; therefore selection bias cannot be entirely excluded. 
However, participants with and without proximal aortic distensibility measures had 
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similar lung function and percent emphysema values, which makes severe selection 
bias unlikely. 
MESA excluded participants with known cardiovascular disease at baseline, which 
may  mean  participants  with  more  severe  aortic  distensibility  or  FEV1 are likely to 
have been excluded, making it more difficult to demonstrate an association between 
aortic  distensibility  and  both  FEV1 and percent emphysema. However, the sample 
was large and measures were precise, making it unlikely that an association of an 
important magnitude was undetected. 
MESA CT measures of emphysema were obtained from the lung fields of cardiac CT 
scans and therefore visualization of the lung apices was limited. Nonetheless, the CT 
percent emphysema measures were highly reproducible and validated (Hoffman et al. 
2009). Lung function was assessed approximately 4 years after the other measures; 
however, the expected mean change in FEV1 over  a  period  of  4  years  in  a  
population-based study such as MESA is small (Jiang et al. 2008). Therefore, 
misclassification due to the 4-year interval is unlikely to explain the observed 
findings. 
Spirometry was performed without administering a bronchodilator, and as such a 
proportion of participants with airflow limitation may have had asthma rather than 
COPD. However, excluding participants with asthma diagnosed before the age of 45 
did not affect the findings. Moreover, none of the previous population-based studies 
employed post-bronchodilator measures. 
6.4.5. Conclusions 
There was no association between FEV1 and ascending proximal aortic distensibility, 
despite the majority of previous published works reporting associations between 
FEV1 and carotid-femoral pulse wave velocity. Nor was percent emphysema 
associated with proximal aortic distensibility, although an association between 
carotid-radial PWV and percent emphysema was reported in Chapter 5. 
Although there were differences in population and in the method used to measure 
arterial  stiffness,  the most plausible explanation for the discrepancy in these results 
was that this study measured stiffness in the proximal ascending aorta, while 
previous studies measured stiffness across larger regions of the arterial tree. 
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The  proximal  aorta  is  the  region  of  the  arterial  tree  with  most  elastin  and  least  
smooth muscle (Apter 1967; Harkness et al. 1957) and is the region most affected in 
primary connective tissue disorders such as Marfan’s syndrome and congenital 
bicuspid aortic valve (Adams et al. 1995; Grotenhuis et al. 2007).  Therefore, the 
previously reported associations between FEV1 and arterial  stiffness are unlikely to 
be mediated by a shared susceptibility in the connective tissue of arteries and lung, at 
least amongst individuals without severe COPD. 
Chapter 7 addresses this question further by measuring associations between lung 
function and measures of vascular pathology at different sites along the arterial tree. 
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7. Cross sectional study in multi-centre general 
population sample: calcification of the aorta 
measured by CT scanning 
7.1. Introduction 
In Chapter 5, an association was reported between percent emphysema and carotid-
radial  pulse  wave  velocity,  a  marker  of  arterial  stiffness,  in  patients  with  COPD.  
Previous authors have reported associations between carotid-femoral PWV and FEV1 
in men (Zureik, Benetos, et al. 2001; Bolton et al. 2009) and increased carotid-
femoral PWV in patients with COPD compared to controls matched on age, and sex 
(Sabit et al. 2007). More recently, carotid-femoral PWV has been found to be higher 
in male ex-smokers with COPD than in male ex-smokers matched on age and pack 
years smoking (Maclay, McAllister, Mills, Paterson, et al. 2009). 
However, in a large population based sample including participants with airflow 
limitation there was no evidence of an association between FEV1 or percent 
emphysema and reduced distensibility in the proximal ascending aorta (Chapter 6). 
One possible explanation for these apparently divergent findings is that the 
relationship between aortic stiffness and lung function, and/or emphysema, differs by 
anatomical site. 
Arterial distensibility can be assessed at different anatomical sites along the course of 
the aorta using magnetic resonance imaging (Rogers et al. 2001), but distensibility 
was measured at only one site in MESA participants. However, aortic calcification is 
associated with aortic stiffness in healthy individuals and in renal disease (Guerin et 
al. 2000; Odink et al. 2008; McEniery et al., Yasmin & and & Maki-Petaja et al., on 
behalf of the Anglo-Cardiff Collaboration Trial Investigators2009), is a feature of 
both atheroma formation and degenerative connective tissue changes 
(elastocalcinosis) and was measured at various aortic sites in MESA. In addition, 
abdominal aortic calcification is itself a strong predictor of cardiovascular mortality 
(Wilson et al. 2001; Rodondi et al. 2007) yet the relationship of FEV1 to  aortic  
calcification has not been established. 
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Therefore, the aim of this chapter is to test the hypothesis that reduced FEV1 and 
percent emphysema on computed tomography (CT) scans are associated with 
calcification of the vasculature from the ascending aorta to the iliac arteries. 
7.2. Methods 
Of the 3,531 participants in MESA-Lung with acceptable spirometry measures and 
without restriction on spirometry, 1,312 were randomly selected to have abdominal 
aortic calcification measures. The recruitment, study design, procedures and 
measurements in MESA lung, were described in Section 6.2.1. 
7.2.1. Aortic calcification 
CT scans of the abdomen were acquired on multidetector (MDCT) and electron 
beam (EBT) scans in 2002 and 2005 in a randomly selected subset of the cohort.  CT 
images were analyzed centrally using a standard protocol by the MESA CT Reading 
Center.   Calcification in the wall  of the distal  abdominal aorta in an 8 cm in length 
segment proximal to the aortic bifurcation was measured (Figure 1-1).  Calcification 
was identified as a plaque of 1mm2 with a density of 130 Hounsfield units (Hu) 
and quantified using the Agatston scoring method (Michos et al. 2008). Calcification 
in the proximal abdominal aorta and each iliac artery was scored similarly. 
Similar methods were used on cardiac CT scans in 2000-02 (Carr et al. 2005) to 
measure ascending aortic calcification and descending thoracic aortic calcification. 
Calcification was identified as plaque of 4.6 mm3 and 5.5 mm3 on  EBT  and  
MDCT respectively as previously described (Takasu et al. 2009). 
7.2.2. Statistical analysis 
Relative risk regression with robust standard errors (log-link and Poisson error 
distribution) was employed to estimate associations between relevant variables and 
the presence of detectable calcification. Among participants with detectable 
calcification the log-transformed magnitude of distal abdominal aortic calcification 
was modelled using linear regression. The exponentiated coefficients are presented, 
and may be interpreted as multiplicative (i.e. ratio) change in average distal 
abdominal aortic calcification. This analysis was performed for consistency with 
previous MESA reports examining arterial calcification, and according to guidance 
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approved by the MESA steering committee (Erbel et al., on behalf of the Multi-
Ethnic Study of Atherosclerosis and the Investigator Group of the Heinz Nixdorf 
Recall Study 2008). 
Sensitivity analyses were performed using emphysema measures corrected for both 
outside and inside air. Interactions were tested with multiplicative terms in regression 
models. 
7.3. Results 
Of the participants in the MESA Lung Study with valid spirometry measures and 
without restrictive lung disease, 1,312 had distal abdominal aortic CT measures.  
Participants with distal abdominal aortic calcification measures were very similar to 
those without (Table 7-1). 
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Table 7-1 Comparison of participants with and without distal abdominal 
calcification measures 






n 2218 1312 
Age, mean (SD), years 61 (10) 61 (10) 
Gender – male, n (%) 1059 (47.7) 676 (51.5) 
Height, mean (SD), cm 166 (10) 167 (10) 
BMI, mean (SD), kg/m2 28 (5) 28 (5) 
Ethnicity, n (%)  
    Caucasian 
    Chinese 
    African-American 











Smoking status, n (%)  
    Never Smoked 
    Ex-smoker 









Pack Years, median (IQR)  18 (7-34) 18 (8-37) 
Spirometry, mean (SD), % 
    FEV1 percent predicted 
    FVC percent predicted 









MRC Bronchitis, n (%) 160 (7.2) 114 (8.7) 
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CT percent emphysema, median 
(IQR), % 15 (8-25) 15 (8-25) 
Asthma (self reported, aged <45) 190 (8.6) 89 (6.8) 
Self reported, n (%) 
    Hypertension  
    Diabetes 
   Antihypertensive medication 











BP, mean (SD), mmHg 
     Systolic Blood Pressure 
     Diastolic Blood Pressure 









Heart Rate, mean (SD), beats/min 63(9) 63 (9) 
Lipids, mean (SD), mg/dl 
    LDL Cholesterol 
    HDL Cholesterol 









CRP, median (IQR), mg/L 1.76 (0.78-3.98) 1.65 (0.76-3.85) 
7.3.1. Lung function and abdominal aortic calcification 
Of the 1,312 participants who had distal abdominal aortic calcification measured, 
903 (68.8%) had detectable calcification. Although the presence of distal abdominal 
aortic calcification was not associated with FEV1 (RR 0.92; 95% CI 0.80 to 1.07; 
p=0.28) lower FEV1 was associated with a greater multiplicative (ratio) increment in 
the extent of distal abdominal aortic calcification after adjusting for study centre, 
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age, sex, race/ethnicity, height, and BMI (FEV1 one litre increment; 0.57 ratio; 95% 
CI 0.45 to 0.72, p<0.001). The strength of the association was attenuated but still 
evident after additional adjustment for cigarette smoking status, pack years, diabetes, 
hypertension, educational attainment, serum low density lipoprotein, high density 
lipoprotein, and glucose concentration, antihypertensive therapy, and lipid lowering 
therapy (0.76 ratio; 95% CI 0.60 to 0.97, p=0.02). 
A weaker association between FEV1 and distal abdominal aortic calcification was 
found amongst never smokers (n=432, 0.91 ratio; 95% CI 0.56 to 1.47, p=0.70) than 
amongst ex-smokers and current smokers (n=612, 0.71 ratio; 95% CI 0.54 to 0.94, 
p=0.02) but the confidence intervals were broad, and an interaction term for 
never/ever smoked and FEV1 was not statistically significant (p-interaction=0.26). 
The FEV1/FVC ratio  was  also  associated  with  the  extent  of  distal  abdominal  aortic  
calcification after minimal adjustment, and similar trends were evident in the full 
model, although the associations were no longer statistically significant (Table 7-2). 
  135 
Table 7-2 Multivariate Analysis – Distal abdominal aortic calcification in 
relation to FEV1, FVC, the FEV1/FVC ratio, and CT percent emphysema 
Exposure (units) 
Estimated multiplicative (ratio) change in 
distal abdominal aortic calcification 
(95% CI), n=903 
p Value for 
Trend 
 FEV1 (litres) 
  Model 1 
  Model 2 
 
0.57 (0.45 to 0.72) 





  Model 1 
  Model 2 
 
0.72 (0.58 to 0.91) 




 FEV1/FVC (ratio) 
  Model 1 
  Model 2 
 
0.76 (0.67 to 0.86) 




Similar associations between FEV1 and vascular calcification were found in the more 
distal iliac arteries.  In contrast, there was no evidence for an association between 
FEV1 and ascending aortic calcification or descending thoracic aortic calcification 
(Figure  7-1).  A  similar  pattern  was  found  for  the  FEV1/FVC  ratio,  but  not  for  the  
FVC (data not shown). 
Similar results for distal abdominal aortic calcification were obtained when 
participants were compared by respiratory condition. Compared to participants with 
normal lung function without self-reported asthma, distal abdominal aortic 
calcification was higher for participants with moderate airflow limitation (1.24; 95% 
CI 0.87 to 1.79), and higher still in those with severe airflow limitation (1.31; 95% 
CI 0.55 to 3.13). 
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7.3.2. Emphysema and aortic calcification 
There was no evidence to suggest that percent emphysema was associated with 
extent of abdominal aortic calcification (1.05; 95% CI 0.72 to 2.06, p=0.47) in 
models adjusting for study site, age, race/ethnicity, gender, height, body mass index, 
cigarette smoking status, pack years, diabetes, hypertension, educational attainment, 
serum low density lipoprotein, high density lipoprotein, and glucose concentration, 
antihypertensive therapy, lipid lowering therapy and scanner type and protocol. 
7.3.3. Sensitivity analyses 
Use of percent emphysema measures corrected for outside air or airways air, or use 
of the 15th percentile point did not affect the results. Additional adjustment for self-
reported use of bronchodilators, steroids, or methylxanthines had little impact on the 
results. There was no evidence for effect modification on an additive scale by gender, 
race/ethnicity,  study  site,  CT  scanner  type  or  severity  of  airflow  limitation  on  
spirometry, nor any evidence of statistically significant departures from linearity for 
any of the main relationships (data not shown). 
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Figure 7-1 Multivariate associations of the forced expiratory volume in one second with presence and multiplicative 
change in aortic calcification from the proximal ascending thoracic aorta to the distal abdominal aorta and iliac 
arteries
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7.4. Discussion 
Reduced FEV1 was associated with greater extent of calcification in the distal aorta. 
In contrast, reduced FEV1 was not associated with proximal aortic calcification, 
consistent with the finding of no association between FEV1 and  PWV  and  aortic  
distensibility reported in Chapter 6. Furthermore, there was a graded increase in the 
magnitude of the association between lung function and the extent of calcification 
from the proximal thoracic to distal abdominal aorta. 
Carotid-femoral  PWV  has  previously  been  found  to  be  associated  with  aortic  
calcification in healthy individuals, with the strongest associations found for 
abdominal aortic calcification (McEniery et al., Yasmin & and & Maki-Petaja et al., 
on behalf of the Anglo-Cardiff Collaboration Trial Investigators2009). A composite 
measure of arterial calcification measured at several arterial sites, including the distal 
abdominal aorta, has been found to be associated with carotid-femoral PWV in 
patients with end-stage renal disease (Guerin et al. 2000). Therefore, if aortic 
stiffness is truly related to reduced lung function, then the findings presented in this 
chapter suggest that the distal rather than proximal aorta is the likely site of the 
pathological vascular changes. 
Moreover, like carotid-femoral PWV abdominal aortic calcification is a 
cardiovascular risk factor (Wilson et al. 2001; Rodondi et al. 2007). Therefore, the 
association between FEV1 and aortic calcification is of interest notwithstanding 
aortic stiffness. 
These findings may generalise to patients with COPD as, despite loss of statistical 
power as a consequence of categorisation, similar results for distal abdominal aortic 
calcification and proximal aortic distensibility were obtained when participants were 
compared by respiratory condition, as defined symptomatically. Therefore, 
pathological changes in the distal rather than the proximal aorta may be implicated in 
COPD. 
7.4.1. Atheromatous plaques 
Vascular calcification occurs in the intima in atheromatous plaques, and in the 
medial elastic laminae. Several previous studies have examined associations between 
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FEV1 and measures of atheromatous disease (Section 1.4.1) but only two have 
examined measures of atheromatous disease in the abdomen/lower limbs. 
In 220 male smokers from a 1914 Swedish Birth Cohort Engström et al. (2001) 
tested for an association between FEV1 and the presence of sub-clinical leg or carotid 
atheroma (composite endpoint) in men. FEV1 was measured via spirometry and was 
standardised by height. Carotid atheroma was assessed using doppler ultrasound, and 
leg atheroma was measured using the systolic ankle–arm pressure index. After 
adjusting for current tobacco consumption, hypertension (high blood pressure), 
diabetes and alcohol consumption, height-standardised FEV1 was  associated  with  
atheroma burden (0.5 litre increase in FEV1; OR 0.76 (95%CI 0.57 to 0.998). 
Schroeder et al. (2005) examined lung function and markers of plaque burden in 
14,480 participants obtained by probability sampling in the Atherosclerosis Risk in 
Communities. Atheroma in the leg was identified via the ankle brachial index (ABI). 
FEV1 was associated with atheroma burden in the leg measured via ABI, even 
amongst never smokers and after adjusting for age, gender, race, study centre, height, 
height-squared, and established cardiovascular risk factors. 
Together with these previous studies which both measured reduced blood flow or 
blood pressure in the lower limbs relative to the upper, and therefore were proxies for 
atheromatous plaques causing stenosis in the arterial tree at any site from the 
descending thoracic aorta to the ankle, the current findings suggest that FEV1 may be 
associated with calcified atheromatous plaque disease. 
FEV1 has previously been associated with increased CRP, circulating platelets, 
leukocyte and fibrinogen (Sin & Man 2003), and TNF- , CRP and oxidised lipids are 
increased in COPD (Gan et al. 2004; Santus et al. 2005). CRP has been implicated in 
atheroma formation (Libby 2002). TNF-  causes smooth muscle cells to undergo 
osteoblastic differentiation and mineralisation thereby promoting calcification (Tintut 
et al. 2000). Oxidised lipids also promote smooth muscle cell osteoblastic 
differentiation, but inhibit this process in bone-derived preosteoblasts (Parhami et al. 
1997), which is of particular interest since osteoporosis is inversely associated with 
arterial stiffness in COPD (Sabit et al. 2007). Therefore systemic inflammation and 
oxidative stress is one possible mechanism linking FEV1 with aortic calcification. 
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7.4.2. Medial elastocalcinosis 
In non-atheromatous regions of artery, a distinct calcification process occurs in 
elastic laminae in the tunica media (Elliott & McGrath 1994), termed medial 
elastocalcinosis. Medial elastocalcinosis is associated with ageing, but like 
atheromatous calcification is believed to be affected by inflammation and oxidative 
stress, and also by dysregulation of promoters and inhibitors of calcification 
(Atkinson 2008). Therefore, as with atheromatous calcification, systemic 
inflammation and oxidative stress might link FEV1 and  COPD  to  medial  
elastocalcinosis. 
A distinct mechanism implicated in medial calcification is elastin degradation, as in 
animal models induced elastolysis causes calcification and ongoing medial 
elastocalcinosis (Atkinson 2008).  However, it appears unlikely that the association 
between calcification and FEV1 is mediated by a shared susceptibility to elastin 
degradation, as hypothesised in Chapter 5, for the following reasons. Firstly, percent 
emphysema, unlike FEV1 and the FEV1/FVC ratio, was not associated with 
calcification, secondly the calcification in the proximal aortic (the vascular region 
with the highest elastin) was not associated with either FEV1, and thirdly, as reported 
in Chapter 6, reduced distensibility of the highly elastic proximal aorta was not 
associated with FEV1 or percent emphysema. 
7.4.3. Limitations 
This study employed the same emphysema measures and spirometry as that 
described in Chapter 6, and as such the same limitations in these measures described 
in Section 6.4.4 apply. 
MESA excluded participants with known cardiovascular disease at baseline. 
However, this is likely to lead to an underestimation of the strength of the association 
between aortic calcification and FEV1. 
Power was limited for patients with severe COPD, and caution is required in 
extrapolating these findings to this group. Nevertheless, there was no evidence for 
any departure from linearity across the range of lung function, and results comparing 
participants with moderate and severe airflow limitation on spirometry were 
consistent with those obtained measuring lung function in the full cohort. 
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In stratified analyses,  extent of calcification was not associated with FEV1 amongst 
participants who had never smoked, although the confidence interval was broad and 
the p-value for the interaction between FEV1 and calcification was not significant. As 
discussed previously (Section 1.4.1), pack years is only an approximate measure of 
lifelong smoke exposure, therefore one cannot exclude residual confounding by 
lifelong smoke exposure as an explanation for the association between FEV1 and 
calcification. 
The independence of the association between FEV1 and cardiovascular risk to 
cigarette smoke exposure, and to a lesser extent the associations between FEV1 and 
atheroma and arterial stiffness, has been shown by demonstrating associations in 
never smokers (Hole et al. 1996; Schroeder et al. 2003; Schroeder et al. 2005; 
Zureik, Benetos, et al. 2001), and a study with a larger sample of never smokers with 
measures of calcification may help address this issue. 
7.4.4. Conclusion 
FEV1 was associated with distal abdominal aortic calcification independently of 
smoking and other cardiovascular risk factors but not with distensibility or 
calcification of the proximal aorta. These findings suggest that increased aortic 
stiffness and related atherosclerotic risk in reduced lung function may be mediated 
by changes in the distal aorta. 
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8. Discussion 
As discussed in Section 1.2, cardiovascular mortality is common in people with 
COPD,  and  FEV1 is a well established predictor of cardiovascular mortality and 
morbidity independent of established cardiovascular risk factors, even amongst never 
smokers. FEV1 may be a broad marker of poor health, or as suggested by some 
authors (Sin & Man 2003; MacNee et al. 2008), COPD may have a causal 
relationship with cardiovascular morbidity and mortality. 
The associations described between FEV1, COPD and cardiovascular health led to 
three broad hypotheses that were addressed in this thesis. 
1 FEV1 is a potentially useful prognostic marker in patients undergoing 
cardiac surgery. 
2 Exacerbation of COPD partly accounts for the association between 
cardiovascular morbidity and mortality and COPD/airflow limitation, and 
acute coronary syndrome is common in exacerbation of COPD. 
3 Pathological changes in the systemic vasculature partly mediate the 
association between COPD/ reduced FEV1 and cardiovascular morbidity and 
mortality. 
8.1. FEV1 and cardiac surgery 
In Chapter 2, an inverse association between FEV1 and both mortality and increased 
length of hospital stay was reported. Moreover, the association was independent of 
existing prognostic markers used in cardiac surgery, and improved discrimination 
and calibration when added to the current most widely used prognostic tool, the 
euroSCORE. This finding is of interest because risk prediction in cardiac surgery is 
important for clinical decision making, auditing and service planning. As such, the 
predictive value of FEV1 should be examined in a confirmatory dataset, preferably 
from more than one centre, and evaluated for inclusion in future risk prediction tools. 
Interestingly, the associations between FEV1 and both mortality and length of stay 
were broadly linear. Previous studies examining FEV1 in population settings also 
found  that  FEV1 predicted adverse events in a broadly linear fashion. Therefore, 
there appears to be no threshold above which a higher FEV1 does not predict a lower 
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risk of adverse outcomes. Consequently these findings argue against a specific 
COPD "effect" on cardiovascular health, and also imply that FEV1 may be a broad 
marker of poor health. 
8.2. Exacerbation of COPD and acute coronary syndrome 
As discussed in Section 1.5.2, two observational studies, both of which used routine 
data, reported that cardiovascular risk may be increased acutely in patients with 
COPD during acute exacerbations, and current COPD guidelines do not address the 
investigation or management of acute coronary syndrome in patients with acute 
exacerbation of COPD. 
The findings from Chapter 3 suggest that there is no clinical consensus amongst 
Scottish Respiratory Consultants regarding whether and how patients with COPD 
should be investigated for the presence of acute coronary syndrome, or as to the 
utility of clinical investigations such as serum troponin or serial electrocardiograms 
in exacerbation of COPD. 
The survey also found that the majority of respondents believed that features in the 
chest pain history could be used to risk stratify patients with exacerbation of COPD 
and chest pain to identify whether it was appropriate to investigate patients with 
exacerbation of COPD for acute coronary syndrome. However, in patients presenting 
with chest pain rather than acute exacerbation of COPD, current guidelines suggest 
that chest pain character is only of limited prognostic value in uncomplicated chest 
pain (NICE 2010), 
In this survey there was no clear clinical consensus regarding the investigation of 
acute coronary syndrome in this survey, and patients with exacerbations therefore 
may be at risk of both under-diagnosis and over-diagnosis. 
The case-series reported in Chapter 4 found that 2.5% of patients admitted to hospital 
with exacerbation of COPD had chest pain, serial electrocardiogram changes and 
raised troponin. Cardiovascular risk factors were also common in this patient group, 
and exacerbation itself may acutely increase the risk of acute coronary syndrome in 
patients with COPD (Huiart et al. 2006; Donaldson et al. 2010). Therefore, although 
non-coronary mechanisms such as right heart strain and acidosis are likely to cause 
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the majority of cases of raised troponin in exacerbation of COPD, coronary 
mechanisms are also implicated. 
Furthermore, approximately 20% of patients with exacerbations had chest pain with 
features usually considered 'high-risk' for acute coronary syndrome (eg exertional, 
radiating to arms or jaw) and no 'low-risk' features, and half of these also had raised 
troponin. Moreover, raised troponin was not associated with chest pain, or serial 
electrocardiogram changes.  
Therefore, the high prevalence in exacerbation of COPD of raised troponin, chest 
pain conventionally considered suggestive of ischaemia, and abnormal ECGs was 
shown to represent a considerable diagnostic difficulty, and the approach advocated 
by the majority of respondents in the survey reported in Chapter 3, risk stratifying 
patients with exacerbations on the basis of features in the chest pain history, appears 
problematic. 
The case-series described in Chapter 4 did not sample patients consecutively, was 
relatively small, and ECGs were not obtained in controlled conditions. However, 
while larger observational studies may more precisely estimate the prevalence of 
raised troponin, chest pain and ECG changes, and may better identify further patient 
characteristics which are associated with raised troponin, they are unlikely to identify 
which clinical features are also indicative of acute coronary artery thrombosis. 
Indeed, given the clinical complexity, only experimental studies (eg clinical trials of 
secondary prevention strategies) are likely to address the question of how best to 
manage patients with exacerbation of COPD and raised troponin. Such trials may be 
justified given the high proportion of patients with raised troponin, and in view of the 
previous report in patients with severe exacerbations in which mortality was 
considerably higher when troponin was raised (Baillard et al. 2003). 
8.3. FEV1 and COPD and vascular pathology 
8.3.1. Arterial stiffness 
As discussed in Section 1.4.2 several studies have examined arterial stiffness in 
relation to COPD and FEV1. Two case-control studies found that carotid-femoral 
PWV was raised in COPD compared to controls, and two European studies in men 
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recruited from the community found that carotid-femoral PWV was associated with 
FEV1. However, FEV1 was not associated with carotid-femoral PWV in a 
population-based study of Japanese-Americans. This thesis employed two measures 
of arterial stiffness, carotid-radial PWV in patients with COPD, and aortic 
distensibility on MR in a population-based sample. 
In Chapter 5, an association between carotid-radial PWV and percent emphysema 
was reported. This finding supports the hypothesis that arterial stiffness is associated 
with lung function and increased in COPD, and the hypothesis that a shared 
susceptibility in the connective tissues of artery and lung might be a mechanism 
linking the two processes. 
However, this finding was in a selected population, and used a technique which 
measured arterial stiffness predominantly across the more muscular brachial artery, 
rather the central arteries. To address these deficiencies, the association between 
distensibility  of  the  highly  elastic  ascending  proximal  aorta  and  both  FEV1 and 
percent emphysema was examined in a group obtained from random sampling of the 
general population in 6 US centres (the MESA study), the results of which were 
reported in Chapter 6. 
FEV1 was  not  associated  with  aortic  distensibility,  nor  was  percent  emphysema  
associated with aortic distensibility. Therefore, the findings reported in Chapter 6 did 
not confirm the results reported in Chapter 5 examining carotid-radial PWV in 
patients with COPD, nor do they confirm the previous reports that FEV1 is associated 
with aortic stiffness. 
MESA performed very comprehensive assessments, allowing adjustment for a wider 
range of potential confounders than in previous studies. Nevertheless, in unadjusted 
analyses aortic distensibility was not associated with FEV1 or with percent 
emphysema, so uncontrolled confounding is unlikely to account for the discrepant 
findings. 
The most plausible reason for the discrepant findings between MESA and previous 
reports is the measures used. Previous case-control studies comparing patients with 
COPD to healthy controls, and cross-sectional studies reporting associations with 
FEV1 in wider populations, employed carotid-femoral PWV to measure arterial 
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stiffness. Carotid-femoral PWV is more widely used than MR aortic distensibility, 
has been shown to predict adverse cardiovascular outcomes longitudinally (Laurent 
et  al.,  on  behalf  of  the  European  Network  for  Non-invasive  Investigation  of  Large  
Arteries 2006) and as the measurement is performed across a larger vascular area, it 
is  likely  to  be  more  sensitive.  However,  aortic  distensibility  is  also  a  validated  
measure of arterial stiffness, and is less vulnerable to measurement bias than PWV 
(Oliver Webb). Moreover, the sample in MESA was very large, making it unlikely 
that the study was underpowered to detect an important association. 
PWV relies on body surface measurements to estimate the length of arteries. FEV1 is 
strongly associated with height, raising the possibility that bias in measurements may 
account for the previously described associations between FEV1 and carotid-femoral 
PWV. Aortic distensibility measured on MR does not employ body surface 
measurements, and was not associated with FEV1. Similarly, in the Copenhagen City 
Heart Study augmentation index, a measure of systemic arterial stiffness derived 
from  the  shape  of  the  pulse  wave-form  at  the  radial  artery,  was  only  very  weakly  
associated with FEV1 (personal communication, Dr Julie Janner, Copnehagen, 
Denmark). If height and body surface measurements are overestimated then FEV1 
adjusted for height (or FEV1 percent predicted) will be underestimated whereas 
carotid-femoral  PWV  will  be  overestimated.  The  converse  is  also  true.  Therefore,  
any error in measurement (eg operator under/over reading) will tend to produce a 
spurious negative association between FEV1 percent predicted (or FEV1 height 
adjusted) and PWV. Therefore measurement error may at least partly account for the 
previously reported associations between FEV1 and  PWV.  Regional  aortic  stiffness  
can be measured using ultrasound and MR, and future studies employing these 
measures may help determine whether FEV1 is associated with aortic stiffness. 
8.3.2. Calcification 
Associations between calcification at several arterial sites from the ascending aorta to 
the iliac arteries were examined in Chapter 7. Calcification in the distal abdominal 
aorta was strongly associated with FEV1,  but not with percent emphysema. Neither 
percent emphysema nor FEV1 was associated with calcification in the more proximal 
regions of the arterial tree. 
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These findings suggest that if systemic vascular changes are related to FEV1, the 
distal  rather  than  proximal  aorta  is  more  likely  to  be  involved,  although  there  was  
less calcification proximally, and the study may have been underpowered to detect an 
association in the more proximal aorta. Nevertheless, the relative sparing of the 
proximal aorta implies that a shared susceptibility in the connective tissue of artery 
and lung, as hypothesised in Chapter 5 is less likely. 
Vascular calcification of the aorta occurs in the intima in atheromatous plaques and 
in the media as elastocalcinosis, the calcification observed could relate to either. As 
discussed in Section 1.4.1 several studies have examined associations between FEV1 
and measures of atheroma, with variable results. Two previous studies have reported 
associations between measures of atheroma in the circulation supplying the lower 
limbs using functional measures, and this study supports these findings by 
demonstrating  calcification  in  the  distal  abdominal  aorta  in  relation  to  FEV1 which 
may be caused by atheroma. 
However, the association between abdominal aortic calcification and FEV1 was 
attenuated by adjusting for potential confounders, particularly by adjusting for 
smoking status and pack years, although it remained statistically significant. Pack 
years is based upon patient recall over decades, and is therefore an inherently 
imprecise measure of lifetime cigarette smoke exposure. As such, residual 
confounding might explain the observed association. To address this issue this 
analysis were repeated amongst never smokers. The estimated co-efficient was in the 
same direction but was severely attenuated, and was not statistically significant. 
This issue of residual confounding by lifelong smoke exposure applies equally to the 
findings from Chapters 5 and 7, and indeed is a limitation common to observational 
studies examining factors related to cardiovascular risk in COPD. Even in studies 
where there is careful matching on pack years smoking, there may be differential 
recall of previous smoke exposure between patients with COPD and controls, 
resulting in similar pack years, but different cigarette smoke exposure histories. 
In population-based studies examining FEV1 and cardiovascular risk, atheroma and 
arterial stiffness, sun-group analyses amongst  never smokers were performed (Hole 
et al. 1996; Schroeder et al. 2003; Schroeder et al. 2005; Zureik, Benetos, et al. 
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2001).  However,  people  with  COPD  are  smokers  and  ex-smokers  almost  by  
definition, and smoking may be a necessary component cause rather than a 
confounder linking cardiovascular risk to COPD. Consequently, observational 
studies examining the association of various cardiovascular risk measures and 
mechanisms to COPD such as vascular stiffness and endothelial function are 
necessarily limited. 
Consequently, additional case-control studies demonstrating differences in vascular 
measures, including endothelial dysfunction, arterial stiffness and atheroma 
measures,  between  patients  with  COPD  and  controls  are  likely  to  add  little  to  the  
current literature. Population based studies examining associations between FEV1 
and vascular measures amongst never smokers may do so, but if null are likely to be 
difficult to interpret because COPD largely a disease of former and current smokers. 
A recent randomised controlled trial in patients with rheumatoid arthritis found that 
infliximab therapy (monoclonal drug therapy with anti-TNF-  activity) caused 
reduced systemic inflammation and reduced carotid-femoral PWV (Wong et al. 
2009), and future studies attempting to definitively address cardiovascular risk in 
COPD will  also  need  to  adopt  experimental  designs  in  order  to  demonstrate  causal  
relationships between airflow limitation and COPD and systemic vascular pathology.  
8.4. Conclusion 
In summary, this thesis demonstrated that FEV1 is associated with higher mortality 
and prolonged length of hospital stay in patients undergoing cardiac surgery. It also 
demonstrated  that  the  high  prevalence  of  chest  pain  and  raised  troponin  pose  a  
diagnostic problem in patients with exacerbation of COPD. Finally, evidence was 
presented suggesting that FEV1 is associated with systemic vascular pathology, 
calcification in the distal aorta. 
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